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Cancer is a leading cause of death worldwide. Chemotherapy remains a major 
therapeutic modality in cancer treatment. Conventional chemotherapeutic agents usually 
have limited efficacy. Furthermore, chemotherapeutic agent- and/or excipient-related 
toxicities comprise a serious problem that may, in many cases, deteriorate the patient’s 
quality of life. In this dissertation, different pharmaceutical technology approaches, 
including nanotechnology and pharmaceutical chemistry, were utilized to improve the 
activity of chemotherapeutic agents. 
 
          Docetaxel is a second generation taxane used as a single agent in breast cancer, 
non-small cell lung cancer, and other cancers. Side effects related to the drug itself and 
one of the excipients (i.e. Tween 80) are extensive. I designed a solid lipid nanoparticle 
(DCX-SLNs) formulation to improve the delivery of docetaxel into solid tumors and to 
avoid excipient-related side effects associated with the current Tween 80-based docetaxel 
 viii 
formulation. The DCX-SLNs showed improved in vitro cytotoxicity in various cell lines 
and significantly inhibited tumor growth in an aggressive mouse model of lung cancer, 
while the Tween 80-based docetaxel formulation was not effective at the dose and dosing 
frequency tested. Higher drug accumulation in tumor tissues was achieved when the 
DCX-SLNs were injected intravenously, as compared to the Tween 80-based docetaxel 
formulation. 
Gemcitabine (2´, 2´-difluorodeoxycytidine, dFdC) is the first line treatment for 
advanced pancreatic cancer. It is also used in other cancers (e.g. ovarian and breast 
cancers). In this dissertation, docosahexaenoic acid (DHA), an omega-3 polyunsaturated 
fatty acid, was conjugated to gemcitabine in the 4(N)-amine group to synthesize a new 
compound (DHA-dFdC). DHA-dFdC shows potent and broad spectrum cytotoxicity 
against all NCI/DTP60 human cancer cell lines.  DHA-dFdC is also 100000-fold more 
cytotoxic than gemcitabine against human and mouse pancreatic cancer cells. In addition, 
DHA-dFdC shows high accumulation in mouse pancreas following intravenous injection, 
prompting the evaluation of its antitumor activity in mouse models of pancreatic cancer. 
In nude mice with subcutaneous or orthotopic human Panc-1 tumors, DHA-dFdC is more 
effective than the molar equivalent dose of gemcitabine in inhibiting the tumor growth.   
In conclusion, the activity of cancer chemotherapeutic agents can be significantly 
improved by formulating them with innovative pharmaceutical technologies.   
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Chapter 1 
Nanomedicine: The Promise and Challenges in Cancer Chemotherapy 1 
 
1.1 Introduction 
 
1.1.1 Nanomedicine and cancer 
       Cancer is a leading cause of death worldwide. Conventional chemotherapy has 
drawbacks ranging from limited effectiveness, chemoresistance, and treatment-related 
side-effects and damages to healthy tissues. The idea of drug targeting started to emerge 
as early as 1906. As outlined by Danhier et al., the challenge ahead is about how to find 
proper targets, to develop a drug that exploits the targets, and finally to design the proper 
delivery system (carrier) for the drug [1]. Cancer nanomedicine is the application of 
nano-sized entities (10-200 nm) to diagnose, prevent, or treat cancer. These entities can 
be loaded with chemotherapeutics, nucleic acids, radiosensitizers, diagnostic agents 
and/or probes. This chapter displays an updated review of several nano-carrier platforms, 
their common features, and applications, followed by a discussion of the major 
mechanisms by which nano-carriers are targeted to the cancer cells. Finally it discusses 
the barriers that hinder the application of nanomedicine in cancer chemotherapy, and how 
the rational design of the nanomedicine may overcome these barriers.    
 
 
 
 
 
1 This chapter is based on “Youssef W. Naguib and Zhengrong Cui, Advances in Experimental Medicine 
and Biology, 2014, 811: 207-233” 
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1.2. General classification of nano-carrier platforms. 
 
1.2.1 Liposomes 
Liposomes are one of the earliest nano-scale drug carriers reported in literature, 
first described by Bangham et al. [2;3]. They are spherical vesicles, composed of closed 
phospholipid bilayer structures that resemble the cell membrane. Their unique structure 
enables the encapsulation of water soluble drugs within their hydrophilic cores, while 
water-insoluble drugs can be entrapped within the lipid bilayer [4]. Nucleic acids (e.g., 
plasmids) can be non-covalently attached on the surface of cationic liposomes via 
electrostatic interaction [5]. Various biocompatible phospholipids, including 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and 1,2-distearoyl-glycero-3-
phosphocholine (DSPG), are in products that have been approved by the United States 
Food and Drug Administration (FDA) for human use [6]. Different types of liposome 
have different sizes. For example, multi-lamellar liposomes have a size range of about 
500-5000 nm, while uni-lamellar liposomes can be as small as 50-100 nm [7]. Liposome 
surface can be modified with polyethylene glycol (i.e., PEGylation) to prolong their 
blood circulation time [8-10]. In addition, liposome surface can be modified with various 
targeting moieties, including small molecules (e.g., anisamide as a ligand to Sigma 
receptors [11-13]) or macromolecules (e.g., monoclonal antibodies in immunoliposomes 
[14;15]) to bind to targets that are exclusively expressed, or overexpressed, by tumor 
cells. Liposomal formulations of anticancer drugs currently in the market include 
PEGylated doxorubicin liposomes (Doxil®, about 100 nm), non-PEGylated doxorubicin 
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liposomes (Myocet®), and non-PEGylated daunorubicin liposomes (Daunoxome®, about 
35-65 nm). The advantages and disadvantages of PEGylation will be discussed in more 
details later.          
 
1.2.2 Polymeric nanoparticles. 
       Various polymers have been used to prepare nanoparticles, including natural 
polymers (e.g., chitosan and albumin) and synthetic polymers (e.g., poly-lactic acid 
(PLA) and poly-lactic-co-glycolic acid (PLGA)). PLA and PLGA are widely used in 
nano- and micro-particle preparation due to their biodegradability, biocompatibility, and 
well-documented safety profile [16;17]. Nanoparticles prepared by polyesters, such as 
PLA, PLGA, and poly-ε-caprolactone (PCL), undergo bulk erosion, where the aqueous 
medium penetrates inside the nano-carriers and causes hydrolysis of the core, which 
brings on further erosion of the bulk [18;19]. On the contrary, nanoparticles prepared 
with other polymeric classes, such as poly-anhydrides and poly-orthoesters, undergo 
surface erosion, which provides a zero-order release pattern [19-21]. Various 
homopolymers (e.g., PLA), co-polymers (e.g., PLGA), and block-co-polymers (e.g., 
PLGA-polyethylene glycol (PLGA-PEG), and PCL-PEG) have been used to prepare 
nano-carriers. Block-copolymers that contain PEG chains may render the nanoparticles 
prepared using them ‘stealthy’ and ‘long circulating’ [22].  
       Emulsion-based methods can be used to prepare PLA or PLGA nanoparticles, 
where a single oil-in-water (O/W) emulsion method is suitable for lipophilic drugs (e.g., 
docetaxel [23]), whereas the double emulsion (W/O/W) method helps the encapsulation 
 4 
of hydrophilic drugs (e.g. siRNA [24]). The double emulsion method involves the use of 
two immiscible liquid phases, where a surface active agent is necessary to form the stable 
emulsion, and nanoparticles are solidified following solvent evaporation [25]. On the 
other hand, the nanoprecipitation (solvent displacement) method involves the use of two 
miscible liquids for the spontaneous formation of nanoparticles, without the use of 
surfactant, as the method does not rely on interfacial phenomenon [25;26]. Other methods 
that can be used to prepare polymeric nanoparticles include spray drying [27] and 
supercritical fluid technology [28]. In addition, micro- and nano-fabrication methods 
(e.g., particle replication in non-wetting templates, PRINT) are developed to produce 
nano-structures with a high level of control over shapes, sizes, aspect ratios, and surface 
chemistry, where nano-discs, filaments, rods, cubes, cylinders, and spheres can be 
produced and rationally employed to tackle drug delivery hurdles. For more information 
on these techniques, the reader is referred to [29-31].     
 
1.2.3 Micelles 
       Micelles are self-assembled nano-aggregates, composed of amphiphilic block-
copolymer or lipid-based molecules, with a lipophilic core and hydrophilic shell to 
solubilize lipophilic drugs. Various micelles that are based on poloxamers [32], 
PEGylated polyesters (e.g., PLA-PEG) [33], or PCL-PEG [34] have been used to deliver 
anticancer agents. For example, Genexol-PM, which is based on PLA-PEG micelles with 
an average size of about 60 nm for paclitaxel delivery, has gained approval for human use 
in South Korea in 2006 [6]. A mixed micelle is a self-assembled nano-structure 
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composed of a mixture of two or more block-copolymers, mixed together to impart the 
favorable features of each single component to the final micellar structure [35]. 
Poloxamers (Pluronic ®, tri-block copolymers of the hydrophilic polyethylene oxide 
(PEO) and the lipophilic polypropylene oxide (PPO), in the form of PEO-PPO-PEO) with 
different grades and PEO to PPO ratios are commonly used for this purpose. Chen et al. 
developed a mixed micelles formulation, composed of Pluronics P105 and F127, for the 
delivery of docetaxel to taxol-resistant lung cancer cells [36]. Due to the high content of 
PPO in P105, high docetaxel content could be loaded. However, the short PEO chains 
were not sufficient to stabilize the micelles. The long PEO chains of Pluronic F127, when 
mixed with P105, successfully improved the stability of the final formulation [36].       
 
1.2.4 Solid lipid nanoparticles (SLNs) 
       SLNs are lipid-based nano-carriers that are solid at room temperature and can 
successfully encapsulate lipid-soluble drugs. Materials used to prepare SLNs include 
mono-, di-, tri-glycerides, or a mixture of them, fatty acids (e.g., stearic acid), and 
phospholipids (e.g., phosphatidyl choline and lecithin). While the method of high 
pressure homogenization (HPH) is widely used to prepare SLNs [37;38], other methods 
have also been described in literature, including emulsion-based methods [39], 
ultrasonication [40], and solvent injection method [41]. Advantages of SLNs include 
cost-effective production, even in large-scale [42]. For more detailed information on the 
application of SLNs in cancer therapy, the reader is referred to [43;44].  
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1.2.5 Drug-polymer conjugates 
       These are composed of a small molecule anticancer agent(s) covalently linked to a 
biocompatible polymeric chain via a bio-responsive linker. Drug-polymer conjugates 
may improve the pharmacokinetics profile of the drug, enhance its stability, and increase 
the accumulation of the drugs in tumor tissues or inside tumor cells [6;45-48]. Various 
drug-polymer conjugates have been investigated since the idea was hypothesized by 
Ringsdorf [49]. One of the very early conjugates is the doxorubicin-(N-(2-
hydroxypropyl) methacrylamide) copolymer conjugate (doxorubicin-HPMA, PK1, 
FCE28068), which is designed to unload the doxorubicin in tumor cells following the 
cleavage of the peptidyl linker by lysosomal cysteine proteinases [50]. Other drug 
conjugates that have been developed include HPMA-doxorubicin-gemcitabine conjugate 
[51], paclitaxel-polylactide conjugate [52], polyethylene glycol-camptothecin (PEG-
camptothecin, Pegamotecan) [46], and paclitaxel-polyglutamic acid conjugate (paclitaxel 
polyglumex, PPX, Opaxio) [45]. Pegamotecan is a PEG-camptothecin conjugate that is 
linked via an ester bond, with a drug loading of 1.7% (w/w). Unfortunately, Pegamotecan 
did not show a promising clinical benefit compared to irrinotecan in patients with gastric 
or gastroesophageal adenocarcinoma in a phase II trial and was subsequently 
discontinued by its sponsor [46]. Opaxio (PPX, formerly known as Xyotax) is a water 
soluble conjugate, composed of paclitaxel (37%, w/v) conjugated in a comb-like manner 
to poly L-glutamic acid via a degradable linker [46;53;54]. Despite very promising data 
in preclinical and early phase clinical studies, data from several phase III clinical studies 
showed that PPX is not significantly more effective than standard treatments [54]. For 
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example, the conjugate did not show any survival benefit, compared to either gemcitabine 
or vinorelbine single agent chemotherapeutic, in a randomized phase III trial in patients 
with advanced non-small cell lung cancer (NSCLC) [55]. Similarly, no survival benefit 
was found when PPX was used as a second line of treatment against NSCLC in a phase 
III trial on 849 patients, compared to docetaxel [56]. Nonetheless, this conjugate is still 
under extensive clinical investigation. 
 
1.2.6 Antibody-drug conjugates 
       Monoclonal antibody (mAb)-drug conjugates (ADC or immunoconjugates) are 
bifunctional molecules that benefit from the targeting capabilities of the mAb moiety and 
the cytotoxic activity of the drug. Candidate mAbs should be chosen to target antigens 
that are exclusively expressed or overexpressed on tumor cells, but not on neighboring 
healthy tissues [57;58]. Advantages of ADCs include the potential to achieve a much 
higher concentration of the cytotoxic agent in tumor tissues ( mainly due to the targeting 
abilities of the mAb), a lower systemic toxicity [59;60], and an overall improved 
pharmacokinetic profile [61]. ADCs can benefit from the long circulatory half-life of 
mAbs [62]. However, the stability of the linker between the mAbs and the drug 
molecules should also match this long-circulation time. Modifications of the linker 
between the mAb and the cytotoxic agent have successfully overcome some of the major 
problems encountered earlier with ADCs. For example, when both the drug and the linker 
were hydrophobic, the maximum drug-antibody ratio (DAR) obtained was 3 to 4, and 
further increase of the ratio resulted in aggregations and short circulation time [63]. The 
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use of hydrophilic linkers helps improve the drug-antibody ratio (DAR) [62-64]. Clinical 
problems associated with ADCs include systemic toxicity, which may be attributed to 
immature drug release and antigen shedding from the tumor tissues into the circulation; 
the shed antigens can reside anywhere in the body and mislead the ‘homing missile’ to a 
false target [57;65;66]. Other disadvantages include unexpectedly low tumor 
accumulation of the cytotoxic agent, with values as low as 0.0003%-0.08% of the 
injected dose per gram of tumor [65]. This led to a shift from using conventional 
cytotoxic agents (e.g., doxorubicin) to other agents with superior toxicity profiles that 
previously hindered their clinical use (e.g., maytansinoids, calicheamicins, and 
auristatins) [58;67]. However, systemic toxicities of these agents, even after mAb 
conjugation, may still prevail. For example, the FDA announced that Pfizer voluntarily 
withdrew Mylotarg® (gemtuzumab ozogamicin) in 2010 for safety and efficacy issues 
[68]. In addition, the low tumor accumulation necessitates the administration of large 
doses of the conjugates, which, in turn, may stir economic problems, especially for long-
term therapy. For example, the estimated single dose cost of an auristatin-CD30 
conjugate (Brentuximab vedotin) is about $13,500 every 3 weeks [69]. Nevertheless, 
ADCs are still regarded as very promising alternatives to conventional chemotherapy, 
with improved anticancer activity and safety profiles.  
 
1.2.7 Inorganic nanoparticles 
These include carbon nanotubes [70], fullerenes [71], gold nanoparticles [72], 
silica nanoparticles [73], iron oxide nanoparticles [74], zirconium nano-platelets [75], and 
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quantum dots [76]. These nano-structures will not be overviewed in this chapter, and 
comprehensive reviews on their application in cancer treatment and imaging can be found 
elsewhere [77-81].   
 
1.3 Mechanisms underlying nano-carrier-based drug delivery to tumors 
 
1.3.1 Passive targeting via enhanced permeation and retention (EPR) phenomenon. 
 
1.3.1.1 Background. The EPR phenomenon was discovered by Matsumura and Maeda in 
1986 [82;83]. Maeda and coworker(s), working on an anticancer protein-polymer 
conjugate called SMANCS (neocarzinostatin-styrene-maleic acid conjugate), noticed that 
many solid tumors exhibit enhanced vascular permeability that resembles the 
inflammatory state of normal non-cancerous tissues. In this context, the elimination of a 
macromolecule (i.e., Evans blue-albumin complex) from normal tissues was found to be 
much faster than that from tumor tissues  [82;84;85].   
       When a tumor starts to form, the tumor cells rapidly proliferate, but the nutritional 
supply (mainly via diffusion) is only suitable for normally proliferating cells [86]. Thus, 
the tumor size is limited to what is called ‘diffusion-limited size’ (about 2 mm) [86;87]. 
In order to satisfy their craving for nutrients, cancer cells recruit new blood vessels, and 
tumor angiogenesis starts to take place [86]. This phase is characterized by excessive 
secretion of angiogenic factors such as vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), in addition 
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to other factors (e.g., bradykinins, nitric oxide (NO), cytokines, matrix metalloproteinases 
(MMP)), which enhance angiogenesis and vascular permeability [87-89]. The mechanism 
of neo-angiogenesis in tumors is discussed in details elsewhere [86;90]. 
       The newly-formed blood vessels have a leaky imperfect structure and abnormal 
basement membrane, while pericytes and smooth muscle layer are deficient or almost 
absent [87;91]. This leaves the tumor blood vessel architecture flawed with fenestrations. 
The size of the fenestrations is heterogeneous and can reach a maximum cut-off value of 
200-800 nm [83], or 1000-2000 nm in some other reports [84;91]. Blood flow within 
tumors is also erratic and tortuous [87]. The imperfect, and fenestrated architecture of 
tumor vasculature helps the extravasation of circulating macromolecules and nano-
carriers into the tumor tissues (i.e., enhanced permeation), which does not happen in 
healthy organs with intact vasculature [83;84;87]. The other facet of EPR is the enhanced 
retention and accumulation of extravasated macromolecules and nano-carriers within 
tumor tissues, which is facilitated by the poor lymphatic drainage and slow venous return 
in tumor tissues [84;89;91]. Small molecules may also benefit from the enhanced 
permeability of the tumor vasculature, but they will fail to accumulate within the tumor 
tissues, as they will be ‘washed out’ quickly by diffusion [83;87;89]. The leaky tumor 
vasculature also gives detached cancer cells access to the circulation, causing metastasis 
[87;91]. The phenomenon has been exploited in many human tumors (excluding 
hypovascular tumors such as pancreatic cancer) for both chemotherapeutic and imaging 
applications [89;92;93].  
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1.3.1.2 Challenges associated with EPR-mediated delivery systems.  
 
Tumor heterogeneity. Heterogeneity is one of the landmarks of tumors in the clinical 
application. Many factors need to be studied before an EPR-based nanomedicine can 
move to the clinic. These factors include the differences in cancers in vasculature 
development and architecture, the effect of the cancer stage on the EPR features, the 
chances of delivering nanomedicine to the metastatic lesion vs. primary tumor sites, the 
effect of tumor stromal density (will be discussed later), in addition to patient-to-patient 
variability, and whether individualized nanomedicine is necessary. Tumor heterogeneity 
may also extend to pre-clinical level, as the animal tumor model selection may have a 
significant effect on decision-making regarding subsequent clinical trials. It is reported 
that subcutaneous xenografts are hastily-formed tumors that usually exhibit an 
exaggerated phenotype of EPR, which may not be of great value in clinical translation 
[94]. Orthotopic tumor models and, more importantly, genetically engineered mouse 
models (GEMM) may be of greater value when studying EPR effect on nanomedicine 
delivery. For more information on the effect of tumor heterogeneity on the EPR effect, 
the reader can refer to [94-97]. In addition, in order to achieve more correlation between 
animal tumor models and cancer patients, factors such as the difference in treatment 
regimens in mice and in humans due to different metabolic rates and the huge tumor/body 
weight ratio in mice compared to humans should be carefully considered in translational 
research [98]. 
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Augmenting the EPR effect. Maeda and co-workers hypothesized that, since tumor 
vasculature lacks an intact basement membrane and smooth muscle layer, when a 
vasoconstrictor agent (e.g. angiotensin II) is systemically administered, the tumor blood 
vessels will not be affected, while other blood vessels in the body will be constricted with 
subsequent increased blood pressure. Thus, the tumor blood flow is expected to increase, 
which in turn will increase the delivery of nanomedicine to tumors via EPR effect [99]. It 
was noticed that the combined administration of enalapril, an angiotensin-converting 
enzyme inhibitor with vascular permeability enhancement effect, and angiotensin II, led 
to a 2-fold increase in the accumulation of a labeled mAb in human colon tumor-bearing 
athymic mice [91;99]. In another report, when a nitroglycerin (NO-generating substance) 
ointment was applied onto tumor-bearing animal skin in an area distant from the tumor 
site, blood flow in tumors was significantly enhanced, but not in muscles [100]. The 
tumor accumulation, as well as the antitumor effect, of a 65Zn-labeled macromolecular 
drug (PEG-Zn-protoporphyrin IX, PZP) was significantly enhanced following topical 
application of nitroglycerin [91;100].  
 
Tumor vascular “normalization” and nanomedicine. While the aberrantly-formed 
tumor vasculature is considered to be a feature that should be taken advantage of in 
nanomedicine delivery, other researchers regarded it as an obstacle that should be 
‘normalized’ in order to pave the way for the delivery of chemotherapeutic agents  to 
tumors. Jain and co-workers were the first to introduce the idea of ‘tumor vascular 
normalization’ in response to anti-VEGF treatment [101;102]. They proposed that the 
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defective tumor vascular architecture may have a detrimental effect on the delivery of 
nanomedicines, and chemotherapy in general, to tumors [102]. According to their 
hypothesis, tumor vascular “normalization” is expected to alleviate tumor hypoxia, and 
thus enhance tumor radiation therapy outcomes, reduce metastasis and the emergence of 
resistance, and ultimately improve tumor chemotherapy [102-104]. In addition, the 
vessels themselves will have less leakiness, normal basement membrane and pericyte 
distribution [94;101]. In normal state, there is a balance between pro- and anti-angiogenic 
factors; however, in tumor state, this balance is shifted towards pro-angiogeic activity to 
promote tumor neo-vasculature formation [105]. The ‘cautious’ use of the anti-
angiogenic treatment modalities (e.g., mAb for VEGF like bevacizumab, Avastin®, and 
VEGF receptor tyrosine kinase inhibitors) is the most common method to shift the pro- 
and anti-angiogenic balance back to ‘normalized’ levels, not to a complete anti-
angiogenicity [103;105]. Although the latter strategy of abolishing tumor vasculature 
may be expected to starve the tumor, it may also harm normal tissue vasculature and 
adversely affect further chemotherapy delivery [101]. Unfortunately, the vascular 
“normalization” effect was found to be transient (about 7-10 days), and during this period 
(called the “normalization” window), concomitant chemotherapy or radiotherapy should 
start [105;106]. However, there is an argument that this technique minimizes the benefit 
of EPR phenomenon in solid tumors, as the leaky tumor vasculature will be almost lost 
[94]. Recently, Jain and coworkers found that tumor vascular “normalization” improved 
the tumor uptake of 10-12 nm nanoparticles (i.e., albumin-bound paclitaxel in 
Abraxane®), but not 100 nm nanoparticles (i.e., Doxil®) [107]. The study highlighted the 
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importance of judicially adjusting the dose of the tumor vascular “normalization” 
treatment, as the use of a higher dose hindered the uptake of even the small nanoparticles 
[107].  
 
1.3.2 Active targeting. 
The term active targeting involves the exploitation of certain proteins or any other 
targets, exclusively expressed, or overexpressed, by tumor cells or tumor vasculature via 
the attachment of a specific ligand onto the surface of the nano-carriers (surface 
decoration); such ligand should bind at a high affinity to the tumor target. The receptor-
bound nano-carriers are then internalized inside tumor cells via receptor-mediated 
endocytosis [108]. While tumor accumulation takes place via EPR, the role of active 
targeting may be thought of as a tool towards the cellular internalization of nano-carriers. 
Various targets have been identified in tumors, including angiogenesis targets such as 
vascular endothelial growth factor receptors (VEGFR), and ανβ3 integrin, epidermal 
receptors such as epidermal growth factor receptor (EGFR) and human epidermal growth 
factor receptor 2 (HER-2), human vasoactive intestinal peptide (VIP) receptors, sigma 
receptors, transferrin receptors, and folic acid receptors [109;110].  
Two main EGFR tyrosine kinases are well-studied and characterized, namely, 
EGFR and HER-2. This family of receptor tyrosine kinases mediate cell signaling 
towards proliferation following the binding of growth factor ligands [109]. Cetuximab 
(Erbitux®, Bristol Myers Squibb, NJ) and Trastuzumab (Herceptin®, Genetech, CA) are 
FDA-approved mAbs against EGFR and HER-2, respectively, and have been used either 
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as a whole mAb or a fraction of an antibody (Fab’) as targeting moieties to decorate the 
surface of nano-carriers to improve tumor targeting [109;111;112]. Several methods have 
been adopted to conjugate mAbs onto nanoparticles, including avidin-biotin interaction 
and covalent conjugation between nano-carriers with thiolated surface and maleimide-
modified mAbs [112;113]. For example, Sandoval et al. designed an EGFR-targeted 
SLNs that contain a lipophilic gemcitabine prodrug (4(N)-stearoyl gemcitabine, 
GemC18) to target human breast cancer cells that overexpress EGFR [114]. Recombinant 
mouse epidermal growth factor (EGF) was first thiolated and purified, and then 
conjugated to maleimide-terminated PEG chains on the surface of GemC18-SLNs. 
Compared to non-targeted GemC18-SLNs, the EGFR-targeted SLNs showed enhanced 
antitumor activity and accumulation in tumors in mice with pre-established human breast 
cancer tumors (MDA-MB-468) [114]. Other tumor cell targets include transferrin 
receptors, sigma receptors, and folic acid receptors (FAR), which can be targeted with 
nano-carriers surface-decorated with transferrin [115], folic acid [116-118], and 
anisamide [11;13], respectively. Currently, a prostate-specific membrane antigen 
(PSMA)-targeted PLGA-PEG nanoparticle formulation that contains the second 
generation taxane docetaxel (BIND-014, BIND Biosciences Inc., MA) is under 
evaluation in clinical trials [119].    
 
1.4 Barriers to delivering nanomedicines to the tumors. 
In this section, the major barriers that hinder the delivery of nanomedicines to 
tumors will be discussed. Once a nanomedicine is administered, it has to pass some 
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physiological barriers to reach the circulation, unless it is administered by intravenous 
(i.v.) injection. Once injected, the nanomedicine has to travel a long way to reach its 
target: the cancer cell. The body starts to react the very first moment the nanomedicine is 
in the circulation, in a way that tends to clear the blood from the newly introduced 
foreign material. Even the fraction of the nanomedicines that makes its way past these 
clearance mechanisms and reach the tumors will encounter a totally different 
environment that should also be tackled in order to get to the tumor cells. Two major 
approaches are generally applied to tackle the tumor microenvironment; one is to breach 
or modify the physical barriers of the tumor microenvironment, paving the way for 
subsequent doses, and the other is to take advantage of some of the unique features that 
characterize the tumor microenvironment to deliver more drugs to cancer cells. 
Unfortunately, getting to the cells will not be the end of the journey, as the cancer cells 
have their own set of defenses that only a nanomedicine with a ‘smart’ design will be 
able to evade. This section will discuss the barriers that nanomedicines encounters on 
their voyage to targets, and how nanomedicines can be designed to reach these targets. 
 
1.4.1 Nanomedicine circulation time. 
 Once in the circulation, nano-carriers are subject to quick surface adsorption of 
plasma proteins, including albumin, immunoglobulins, and complement proteins 
(opsonins), in a process called opsonization [120]. The ‘opsonin-tagged’ nano-carriers are 
then recognized and phagocytosed by the mononuclear phagocytic system (MPS) cells 
(e.g., monocytes and macrophages), which carry them to the MPS organs (e.g., liver, 
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spleen, and lymph nodes), significantly shortening the circulation half-life of the nano-
carriers [121;122]. The accumulation of non-degradable nano-carriers in MPS organs 
may lead to toxicity [123]. In addition, glomerular filtration of nano-carriers smaller than 
5.5 nm (renal filtration cutoff size) can take place, while much larger particles (~1 µm)  
are quickly opsonized [120;124]. Although the 5.5 nm cutoff size seems too small, some 
nano-carriers may fall within this range and are filtered in the kidney (e.g. quantum dots, 
and carbon nanotubes [122]). Several factors determine the rate of opsonization of nano-
carriers by plasma proteins, including surface characteristics (hydrophobic vs. 
hydrophilic), zeta potential, particle size, and shape [120;123]. In general, opsonization 
occurs more efficiently and much faster to particles with hydrophobic surfaces than to 
those with hydrophilic surfaces [123]. This was the basis for the surface modification of 
nano-carriers with a hydrophilic molecule, which is the most widely-used strategy to 
prolong the circulation time of nano-carriers. PEG is the most successfully used molecule 
to achieve this goal, and the process is called PEGylation. The technique was first 
exploited by Klibanov et al. in 1990, where a PEG moiety is covalently conjugated to a 
phospholipid (e.g., dioleoyl phosphoethanolamine, DOPE) that was incorporated into 
large uni-lamellar liposomes [10]. About 85% and 49% of PEGylated liposomes were 
found circulating in mouse plasma 1 h and 5 h after injection, respectively, compared to 
about 20% and 0% for their non-PEGylated counterparts [10]. It is thought that the 
protruding PEG chains sterically hinder the adsorption of plasma proteins to the nano-
carrier surface [10], and the hydrophilic nature that they impart to the nano-carrier 
surface minimizes non-specific interaction with MPS cells [10;125]. The term STEALTH 
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has been employed to describe such PEGylated, long-circulating nano-carriers, as 
PEGylation has become a very solid dogma in the rational design of nano-carriers for the 
delivery of tumor chemotherapeutics. Various researchers studied factors that govern 
efficient PEGylation. Desimone and colleagues studied the effect of PEGylation density 
on protein binding, macrophage uptake, and circulation time of PEGylated hydrogel 
nanoparticles (80 × 80 × 320 nm) produced by PRINT technology, where the 
nanoparticles were PEG-functionalized in two different conformations, brush and 
mushroom [126]. The researchers found that protein binding to the surface of 
nanoparticles is inversely proportional to PEG density, and interestingly, efficient protein 
binding inhibition and prolonged circulation were achieved at a less PEG density than 
what was previously reported [126]. Drug release from the nano-carrier is yet another 
factor that should be carefully considered in nano-carrier design. Since very fast drug 
release can result in complete dumping of the drug  in the circulation before the nano-
carriers reaches their  target, a prolonged circulation time should be matched with slow 
drug release to prevent pre-mature drug leakage [44]. 
 PEGylation strategy is not problem-free; it was found that repeated doses of 
PEGylated nano-carriers (e.g., Stealth liposomes, micelles, or nanoparticles) may elicit an 
immune response [127]. This phenomenon, commonly known as accelerated blood 
clearance (ABC), may result in rapid clearance and loss of clinical benefit of subsequent 
doses [128]. The details of the phenomenon, in addition to methods to overcome its 
detrimental effects, are reviewed elsewhere [127]. 
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Bio-mimetic particles, which are ‘camouflaged’ micro- or nanoparticles that 
resemble biological entities, such as viruses, bacteria, red blood cells (RBC’s), and 
leukocytes, have been extensively studied for drug delivery purposes. Since these 
previously mentioned biological entities have tremendous capabilities to evade most 
biological and cellular barriers in the mammalian bodies, the ‘camouflaged’ 
nanoparticles, if properly designed, can be expected to do the same [129]. This strategy, 
along with the judicious control of shape and size of the nano-carriers, has been adopted 
to increase the circulation time of drug-loaded nano-carriers and improve overall drug 
delivery to tumors [124]. To mimic filamentous viruses, Discher and co-workers 
developed a PEGylated flexible filamentous micelle formulation (filomicelles), of at least 
one dimension in the nano-range and the other may extend to microns, that was able to 
evade MPS cell uptake and circulate longer in the plasma, and consequently, deliver 
more drugs to tumors via EPR [130]. The PEG-PCL filomicelles showed persistent 
circulation in the plasma for up to a week, while their spherical counterparts were only 
there for one tenth of this time [131]. The paclitaxel-loaded filomicelles showed superior 
proapoptotic and tumor-shrinking activities in tumor-bearing nude mice, as compared to 
free paclitaxel, which was completely ineffective [131]. Recently, Taciotti and co-
workers synthesized leukocyte-camouflaged non-porous silicone nanoparticles (leukolike 
vectors, LLV) coated with a leukocyte cellular membrane to impart cell-like functions to 
the nano-carrier [132]. These particles exhibited significantly less opsonization and 
cellular uptake by murine macrophages and human phagocytic cells. These particles may 
be promising in delivering drugs to tumors, not only because they undergo delayed liver 
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clearance and enhanced tumor accumulation in mice, but also because their tumoritropic 
accumulation is driven by the EPR effect and is also dependent on their ability to 
recognize and bind to tumor endothelium in an active form [132].  
 
Other biological barriers. Other biological barriers in the delivery of nanomedicines to 
tumors include the blood brain barrier (BBB) or blood brain-tumor barrier (BBTB) 
following i.v. administration. Due to the presence of BBTB, characterized by the 
presence of endothelial cells tight junctions and low permeability into the tumor 
parenchyma, with vascular pore size of about 12 nm, the EPR effect may not be useful in 
increasing the delivery of nanomedicines in brain tumor tissues [120]. The use of 
targeting ligands to enable the translocation of the nano-carriers across the endothelial 
cells of the tumor vasculature is becoming a very promising technique [133-135]. Among 
the most exploited endothelial targets in tumors are ανβ3 and ανβ5 integrins, and D-
glucose transporter protein (GLUT), where RGD (argentine-glycine-aspartic acid) 
peptide motifs [134] and deoxy-D-glucose are used to modify the surface of nano-carriers 
to facilitate such active-targeted uptake [133].   
 
1.4.2 Nanomedicine and tumor microenvironment  
 
1.4.2.1 Background. A better understanding of the tumor micro-structure is a 
cornerstone in the design of a successful nanomedicine. A tumor cannot be described as 
myriads of cancer cells, all packed together, and localized in a specific region. Tumors 
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can be considered as organs, with both well- and ill-formed structures, and various kinds 
of cells, including tumor cells, tumor fibroblasts, inflammatory cells (e.g. macrophages), 
blood and lymphatic network of vessels, held together within a complicated cross-linked 
extracellular matrix (ECM) [103;136;137]. In this section, various features of the tumor 
microenvironment will be overviewed in order to make a better use of the diverse toolbox 
that nanomedicine may provide to potentially conquer cancer. 
 
ECM. The ECM components include various proteins (e.g., collagens), 
glycosaminoglycan-containing glycoproteins (e.g., hyaluronic acid (HA) and 
proteoglycans), the glycoprotein SPARC (secreted protein, acidic and rich in cysteine), 
and polysaccharides [138-140]. ECM components are usually differentiated into 
basement membrane and interstitial matrix [141]. Collagen type I, in addition to 
fibronectin, imparts mechanical integrity of the interstitial matrix of tumors [140]. A 
major determinant in the heterogeneity of tumor matrix rigidity is the expression level of 
matrix metalloproteinases (MMPs), which are overexpressed in many tumors and are 
responsible for collagen fibrils proteolysis within the tumor matrix [138;141;142]. 
Overexpression of MMPs is usually associated with decreased matrix rigidity, increased 
potential for cancer cells migration and metastasis, and the prevention of apoptosis [143]. 
ECM stiffness is also attributed in part to the overexpression of lysyl oxidase (LOX), 
which is responsible for hyaluronic acid and collagen fibers cross-linking [141;144]. 
Overexpressions of MMPs and LOX are correlated with poor cancer patient prognosis 
[141;142]. The interplay between ECM components verifies the overall state of tumor 
 22 
heterogeneity and plays a major role in determining the outcomes of chemotherapy. 
Tumor cells are shielded within this matrix and connected to the blood circulation 
through the previously discussed aberrantly-formed vasculature.  
       
Tumor hypoxia, acidity, and increased interstitial fluid pressure. Three major 
features characterize the nature of the tumor matrix, namely hypoxia, extracellular 
acidity, and increased interstitial fluid pressure (IFP). Hypoxia is a feature of many solid 
tumor cores, where the ill-formed vasculature become unable to deliver oxygen and 
nutrients to deep tumor tissues, which lie more than 100 µm from the nearest blood vessel 
[145;146]. These cells can no longer depend on oxidative metabolism to produce ATP, 
and rather revert to glycolysis, which, along with nullified lymphatic drainage, results in 
the accumulation of lactate within the deep tumor tissues, lowering the extracellular 
matrix pH [145]. Although hypoxic cells are viable, they are usually accompanied with 
necrotic tissues. Unfortunately, these untoward conditions results in the selection of 
‘elite’ cancer cells with outstanding resistance capabilities, as hypoxia induces tumor 
evolution, oncogene expression, apoptosis resistance (via selection of cells with lost p53 
sensitivity) [147], and metastasis [144;148;149].  
 Both hypoxia and the acidic extracellular environment contribute to cancer 
chemoresistance via several mechanisms. Hypoxia stabilizes hypoxia-inducible factor 1α 
(HIF1 α), which leads to the upregulation of drug resistance genes, including multi-drug 
resistance 1 (MDR1) gene and P-gp-encoding gene [145;150]. Drugs that rely on free-
radical formation will experience reduced activity (e.g., bleomycin), whereas those that 
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are weak bases (e.g. doxorubicin) will be ionized in the extracellular matrix, and thus 
their internalization will be hindered [138;151]. In addition, hypoxic conditions tend to 
abolish the efficacy of radiation therapy [101].  
 Another common feature of most solid tumors is the increased interstitial fluid 
pressure (IFP), which can massively hinder the efficient delivery of chemotherapeutics 
[152;153]. The defective lymphatic drainage, the accumulation of metabolic products in 
the hypoxic environment, and the imperfect structure of the hastily-formed vasculature 
significantly contribute to this phenomenon [138;153;154]. The rapidly dividing tumor 
cells and the dense cross-linked ECM structure not only compress the blood and lymph 
vessels, but also do not expand enough to allow edema formation, which can alleviate the 
increased IFP [98;154]. The fenestration that characterize the leaky tumor vasculature 
may not be enough to deliver nano-carriers to the tumors in such cases, as the expected 
extravasation into tumor tissues may also be accompanied by an intravasation into the 
blood vessels, which demolishes any benefit that the nano-carriers may have to reach 
tumors [98]. Variability of IFP  contributes to the heterogeneity of tumors and 
complicates the predictability of clinical outcomes from chemotherapy  [146]. 
 
Tumor associated macrophages. Tumor-associated macrophages (TAMs) are part of 
the inflammatory cells in the tumor microenvironment. The link between inflammation 
and cancer development is well-established [155;156]. TAMs usually originate from 
peripheral circulating monocytes that are recruited by the tumors [157]. However, some 
of them may locally proliferate within the tumor environment [158]. Although 
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macrophages may be expected to fight against the rapidly- and aberrantly-proliferating 
tumor cells, interestingly enough, there is strong evidence that tumor cells are not only 
able to block the antitumor activity of the immune cells, but also ‘enslave’ the TAMs to 
serve their cause by helping the tumor cells proliferate, nourish, and progress [157-159]. 
TAMs improve tumor angiogenesis, invasiveness, metastasis, and immune system 
suppression, and have been linked with poor prognosis [155;160;161]. Several 
chemoattractants expressed by tumor and endothelial cells are involved in TAM 
recruitment, which include monocyte chemoattractant protein-1 (MCP-1, CCL2), 
macrophage inflammatory protein-1α (MIP-1α, CCL3), vascular endothelial growth 
factor (VEGF), and colony stimulating factor 1 (CSF-1) [157;160]. The evident role of 
TAMs in tumor progression qualifies them as a potential target for nanomedicine-based 
chemotherapy.  
 
Cancer-Associated fibroblasts. Cancer-associated fibroblasts (CAFs) are the most 
abundant cells within the stroma in many tumors, including breast and pancreatic cancers, 
and are the main source of ECM components [162-164]. Fibroblasts are mesenchymal 
non-inflammatory cellular components of the connective tissues, although they regulate 
inflammation and wound healing, and they secrete fibrillar components of the ECM (like 
type I, III, and IV collagens) [163]. They become activated in wound healing and fibrosis 
(called myofibroblasts) and start de novo expression of a type of filamentous actin, α-
smooth muscle actin (α-SMA) [162;164-166]. Since cancer may be regarded as 
‘inflammation that never heals’ [167], CAFs share a lot of similarities with activated 
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fibroblasts associated with wound healing, including α-SMA expression (commonly used 
to identify CAFs) [163;165;168] to act as a scaffold for other ECM components. 
However, they do not deactivate or undergo apoptosis, like activated fibroblasts, after 
inflammation subsides [164], mainly because tumors are persistent. Fibroblasts in tumor 
stroma may exist as activated or non-activated form, but the vast majority of CAFs are 
the activated form (e.g., 80% of fibroblasts in mammary tumors are in the activated form) 
[163;168]. CAFs are involved in tumor progression and metastasis via secretion of a 
panel of cytokines that stimulate the excretion of MMPs, which predispose metastasis 
and provide support for tumor cell proliferation [168;169].   
 After this brief overview of the tumor microenvironment, it should be clear that 
exploiting the anticancer activity of a nanomedicine in cell culture is not sufficient. In the 
literature, the in vitro cytotoxic evaluation is usually accepted as a means to ensure that 
the chemotherapeutic agent still retains its activity within the formulation. In the 
following section, the role of nanomedicine in overcoming the tumor microenvironment 
barriers, including ongoing clinical trials, will be overviewed. 
 
1.4.2.2. Application of nanomedicines to breach or to take advantage of tumor 
microenvironment barriers to improve drug delivery.  
       A successful anticancer agent should be able to simultaneously deal with as much 
of these barriers as possible. Combination drug or drug/adjuvant therapy can provide a 
multi-target modality. However, toxicity associated with such cocktails can be expected. 
The versatility of nanomedicine-based approaches may help tackle multi-functional tasks 
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with minimum toxicity. In this section, nanomedicine approaches to breach tumor stroma, 
or to take advantage of some of the conditions specific to tumor microenvironment will 
be overviewed. 
 
1.4.2.2.1 Depletion or modification of tumor stroma.  
 
Hyaluronic acid. Hyaluronic acid (HA) is abundantly accumulated in almost all 
epithelial tumors (e.g., pancreatic ductal adenocarcinoma, PDAC), providing a 
viscoelastic matrix within the collagen fibers in the tumor, and is correlated with tumor 
proliferation, invasiveness, and poor prognosis [170;171]. HA also contributes to tumor 
progression, and its water retention capability helps increase the IFP [171]. The use of 
bovine hyaluronidase (HYAL) to breach the tumor ECM was assessed in various clinical 
trials during the late 1990’s. Although promising results ranging from low or absent 
recurrence to prolonged patient survival were obtained when HYAL was combined with 
other anticancer drugs [172;173], the development of allergic reactions to bovine HYAL, 
which can be serious in many cases, hindered the widespread acceptance of this approach 
[170]. Researchers at Halozyme® Therapeutics developed a human recombinant HYAL 
(rHuPH20, Hylenex®) that was well tolerated in 100 human volunteers following 
intradermal injection [174] and was approved by the FDA later on. However, due to the 
very short half-life of this product, its use for cancer treatment was not feasible [171]. To 
further improve this product, the researchers, via conjugation of a 30K N-
hydroxysuccinimidyl ester of methoxy-polyethylene glycol-butanoic acid to rHuPH20, 
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designed a PEGylated form of the enzyme (PEGPH20), which exhibited a 270-fold 
increase of in vivo half-life in mice, enabling its intravenous administration [171]. The 
PEGylated recombinant human hyaluronidase dramatically lowered the IFP via cleavage 
of the HA chains, releasing the entrapped water and decompressing the previously 
collapsed tumor vasculature, in transgenic mice with metastatic and invasive PDAC 
[175;176]. The combination of PEGPH20 with gemcitabine dramatically suppressed 
metastasis and significantly prolonged the survival of transgenic mice with PDAC, 
compared to gemcitabine alone (91.5 days vs. 55.5 days, respectively, p = 0.004) [175]. 
The administration of PEGPH20 3 h before liposomal doxorubicin showed a 4-fold 
increase in doxorubicin accumulation in high HA-tumor xenografts, compared to 
liposomal doxorubicin alone [171]. In a different context, Yang et al. designed a lipid-
based nano-carrier for the taxane drug paclitaxel. They decorated the surface of the nano-
carriers with oligo-fragments of HA (oHA) that result from the breakdown of the latter by 
HYAL [177]. They proposed that the use of oHA, which can replace the endogenous HA 
on its binding sites in CD44 receptors overexpressed on cancer cells, will not only 
provide an efficient targeting modality for HA-rich breast tumors, but also help breach 
the HA coat on tumors by CD44 receptor competition [177]. This strategy successfully 
sensitized the tumors to paclitaxel nano-carriers, which showed a significantly stronger 
anticancer activity compared to the non-decorated nano-carriers [177]. 
 
Hedgehog pathway. Stromal depletion becomes critical in dealing with deadly tumors 
like PDAC, where the stromal structure is tremendously dense. PDAC is one of the 
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deadliest cancers, with a median survival of few months, which can be extended for few 
more weeks when the standard first line treatment gemcitabine is used [178]. The 
fibroblasts-rich, rock-solid, almost avascular, desmoplastic tumor stroma acts as a 
mechanical barrier against the intratumoral delivery of gemcitabine, which already 
suffers from a short circulating half-life and extensive deamination [139;179;180]. Olive 
et al. (2009) described the efficient, yet transient, restoration of the diminished 
vasculature in a transgenic mouse model, via the co-administration of a hedgehog (Hh) 
pathway inhibitor IPI-926 with gemcitabine [180;181]. Inhibition of the stromal-
associated pathway depleted the stromal matrix in the mouse model, which closely 
resembled human PDAC, and resulted in delivering more gemcitabine to the tumors, 
inhibiting the tumors growth, and prolonging the median survival of mice [181]. 
Unfortunately the tumors reverted back to the avascular state at the end. However, the 
positive results may provide new hopes to defeat the malign tumors. In a commentary on 
that study, Olson and Hanahan highlighted two mean aspects, dealing with the hedgehog 
pathway paradigm; the first one being that the tumor fights back to restore the hypoxic 
state, instead of the opposite in order to fulfill its craving to nutrients [180;181]. The 
other aspect is that this approach tends to ‘vascularize’ the tumor by inhibiting an anti-
angiogenic pathway, which is contrary to the commonly known dogma of tumor vascular 
‘normalization’, proposed by Jain, via treatment with angiogenic inhibitors to balance the 
‘super-active’ pro-angiogenic activity of tumors [103;104;152;180;181]. Although 
positive results have been reported in early clinical studies with GDC-0449 (vismodegib, 
Genentech®) plus gemcitabine, or saridegib plus gemcitabine, phase II clinical trials with 
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the latter combination in previously untreated patients with metastatic PDAC failed to 
show any advantage and were stopped short [139]. This is not the end for Hh inhibitors 
though. Vismodegib was granted the FDA’s priority review program approval in 2012 to 
treat advanced basal-cell carcinoma, and other Smoothened (Smo, the transmembrane 
protein whose reversal of repression is a major step in the Hh pathway) inhibitors (e.g., 
LDE 225, Novartis®) are still under clinical trials [182]. In the same regard, a 
nanomedicine formulation of a hedgehog inhibitor showed some promises in pre-clinical 
studies [183;184]. The PEGylated polymeric nanoparticle formulation (PLGA-PEG) of a 
hedgehog pathway inhibitor HPI-1 could overcome the mutational resistance of 
orthotopic pancreatic tumors against commonly used Hh inhibitors in mice [184], and 
inhibited metastasis in a hepatocellular carcinoma model [183].  
 
SPARC. Secreted protein, acidic and rich in cysteine (SPARC), also known as 
osteonectin, is a glycosylated 43 kDa protein that is overexpressed in the PDAC stroma 
and at the invasion front of the tumor. It is usually associated with poor prognosis 
clinically in patients with high expression in the peritumoral fibroblasts, rather than in 
cancer cells [185-187]. Two groups of ECM-associated proteins are known: 1) structural 
proteins (e.g., collagens), and 2) non-structural or matricellular proteins (e.g., SPARC) 
[188]. Albumin-bound paclitaxel (nab-paclitaxel, Abraxane®), in an active combination 
regimen with gemcitabine, achieved 12.2 months overall survival (OS) and 48% 1-year 
survival (compared to 5.7 months and 20%, respectively, with the standard therapy with 
gemcitabine) in a phase I/II clinical trial [189]. Furthermore, a phase III clinical trial in 
 30 
patients with metastatic PDAC revealed that the combination achieved an OS of 8.5 
months (431 patients) vs. 6.7 months with gemcitabine monotherapy (430 patients), and a 
1-year survival of 35% with the combination therapy vs. 22% with gemcitabine alone 
[190]. The fact that albumin-bound nano-carriers are transcytosed into the cells following 
binding to albumin specific receptors (e.g. gp60) [186] may not be enough to explain the 
improved clinical benefit achieved in the clinical trials, as the question remains: how 
could the 10-nm circulating albumin-paclitaxel complexes penetrate into the dense 
desmoplastic stroma that not only comprises a physical barrier against deep tumor 
penetration, but also keeps the tumor cells away from the already-poor vasculature? In a 
preclinical study concurrently carried out with the same phase I/II clinical study 
mentioned above using nab-paclitaxel with gemcitabine, Von Hoff et al. found that the 
use of nab-paclitaxel depleted the stroma of a pancreatic cancer xenograft tumors in nude 
mice, which facilitated the gemcitabine delivery to the tumors (2.8 times higher than 
what was achieved with gemcitabine alone). The stromal depletion effect was associated 
with dilated blood vessels and increased endothelial cell content in the stroma. The 
stromal depletion and improved vascularization are believed to improve gemcitabine 
penetration into the tumors and brought the tumor cells closer to vasculature [189]. The 
cornerstone finding in this study was that SPARC was the Achilles’ heel within the dense 
stroma of the PDAC, as the strong affinity between the overexpressed SPARC and 
albumin in nab-paclitaxel brought the nano-aggregates (i.e., nab-paclitaxel) deeper into 
the tumors, breaching the stroma, and bringing more gemcitabine deep inside 
[186;189;191]. Similar findings were also reported with head and neck cancer tissues 
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[187]. Another factor that contributes to the improved efficacy of gemcitabine when nab-
paclitaxel was concurrently administered is that the nab-paclitaxel was found to lower the 
cytidine deaminase levels in a murine pancreatic cancer model [192]. Cytidine deaminase 
is responsible for the extensive deamination of gemcitabine (more than 90%), yielding 
the inactive compound 2'-deoxy-2',2'-difluorouridine (dFdU) [179;193].  
 
α-SMA. Li and colleagues developed a PEG-docetaxel-acetylated 
carboxymethylcellulose conjugate that can self-assemble and form nanoparticles of about 
120 nm. This formulation (Cellax) was shown to be more efficacious than commercial 
solvent-based docetaxel and nab-paclitaxel in both in vitro and in vivo studies [194-197]. 
Docetaxel conjugation percentage was high (> 30 wt%), and it was completely and 
slowly released following a near zero-order pattern within 3 weeks [197]. In a recent 
study that thoroughly investigates the tumor stroma involvement in the anticancer activity 
of Cellax, the authors reported that Cellax significantly depleted the stroma of 
orthotopically implanted mammary tumors (4T1 and MDA-MB-231), with an about 70-
fold increase in tumor perfusion and about 3-fold suppression of IFP, while minimum or 
no effect was noticed following either solvent-based docetaxel or nab-paclitaxel, in the 
same tumor models [169]. In addition, and more importantly, lung metastasis was also 
reduced  by 7- to 24-fold following Cellax treatment, whereas the solvent-based 
docetaxel increased the number of metastatic lesions in the lungs [169]. One day after 
intravenous injection of Cellax, the authors found that the vast majority of Cellax 
nanoparticles (85%) co-localized with α-SMA-positive stromal cells, and the α-SMA 
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content in tumors declined from about 30% down to 0% within 1 week, which indicates 
the stromal-depleting effect of the nanoparticles [169]. Interestingly, tumor epithelial 
cells population started to decline only 7 days after the initiation of the treatment (i.e., 
after α-SMA depletion took place). Early investigation of the mechanism of Cellax-
stroma interaction revealed that the albumin adsorbed on the circulating Cellax may favor 
the albumin-SPARC stromal penetration pathway [169], similar to that reported for the 
nab-paclitaxel [189]. The fact that SPARC expression is also associated with α-SMA-
positive CAFs supports this proposed mechanism [169]. However, the failure of nab-
paclitaxel to outweigh the Cellax performance in this tumor model sheds some questions 
on the influence of the tumor model on the stromal-depletion effect of the former.         
1.4.2.2.2 Stimuli-responsive nano-carriers. 
This approach takes advantage of specific characteristics that are exclusively 
exhibited in the tumor microenvironment to improve the antitumor activity of the 
chemotherapeutics. Various tumor environmental stimuli are involved in this approach, 
including lower extracellular pH, hypoxia, and MMP overexpression. Stimuli-sensitive 
nano-carriers have been extensively reviewed in literature (see [198-201]). This section 
provides a brief overview of the most common approaches employed to increase nano-
carrier penetration into tumors. 
Andresen et al. developed a liposomal formulation, composed of a serum-stable 
prodrugs of a group of cytotoxic lipid agents (anticancer etherlipids, AELs, also called 
cytotoxic lysolipids) for selective tumor site-activation and release of the active drug 
[202;203]. The AELs were made into phosphorylated prodrugs (proAEL) by 
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modification with a stable ether bond that is not hydrolysable in plasma, but is sensitive 
to a class of phospholipase A2 (PLA2), called secretory PLA2 (sPLA2), which is 
overexpressed in the tumor microenvironment. The prodrugs self-assemble into 
liposomes that can accumulate via EPR into tumor tissues, where the sPLA2 hydrolyzes 
the prodrugs, releasing the potent AELs in the tumor microenvironment [202]. 
Furthermore, the fatty acid by-products of the hydrolysis may also act as tumor cell 
permeation enhancers to improve the cellular uptake of AELs. This formulation 
successfully overcame the red blood cell toxicity issues encountered with the use of 
AELs, as the ether-based prodrugs are stable in plasma, and the liposomal nature of the 
prodrugs enables the encapsulation of water soluble drugs into the core of the liposomes 
[202;203].  
   Several pH-sensitive block-copolymers have been utilized to deliver drugs in 
the acidic extracellular matrix, while pre-mature drug leakage is minimized. Bae and co-
workers developed a novel doxorubicin-loaded mixed micelle formulation that is 
destabilized in acidic pH to release doxorubicin [204]. The mixed micelle system was 
composed of poly (L-histidine)/PEG and poly (L-lactic acid)/PEG (polyHis/PEG and 
PLLA/PEG). As the polyHis moiety is protonated in the acidic condition, the critical 
micelle concentration (CMC) of the amphiphilic molecule increases, which disassembles 
the whole micelle structure [200;204;205]. The pH at which the formulation destabilizes 
can be controlled by varying the ratio between the two block-copolymers [204].  
The idea of pH-dependent shedding of PEG chains has been described in 
literature for several purposes [200;206-209]. Poon et al. designed a layer-by-layer (LBL) 
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nanoparticle platform, where the cationic poly (L-lysine), functionalized with iminobiotin 
(inner layer) is further decorated with biotin-functionalized PEG chains (outer layer), 
through a neutravidin linker (middle layer) [206]. The quantum dots-loaded nanoparticles 
are designed to shed PEG chains via decomposition of the acid-sensitive iminobiotin-
neutravidin at the acidic pH of the hypoxic tumor microenvironment. This will bring the 
cationic poly (L-lysine) layer to surface, which improves the nanoparticles internalization 
[206], as the PEG layer, although useful for prolonged circulation, is expected to hinder 
efficient cellular uptake [39;210]. A conventional biotin-avidin-based PEGylation 
strategy was used to prepare non-pH-sensitive nanoparticles for comparison. Although 
the tumor accumulations of nanoparticles in the first 8 h were not different between the 
pH-sensitive and non-sensitive formulations, the pH-sensitivity improved the 
nanoparticles accumulation after 24 and 48 h. Furthermore, histological evaluation 
showed that the pH-sensitive nanoparticles were associated with hypoxic regions. Early 
accumulation (within 8 h after injection) was assumed to be independent of the pH-
sensitivity, and was rather dependent on the EPR effect, which is not expected to favor 
the delivery of either formulation [206].  
In the same regard, Sawant et al. designed a multifunctional ‘smart’ nano-carrier 
that has a long-chain PEG-phosphoethanol amine (PEG-PE) moiety attached to an mAb 
for active targeting, while shorter PEG-chains are attached to a cell penetrating peptide 
(e.g., Tat peptide) [207]. The design involved inserting a pH-sensitive hydrazone bond in 
between the long-chain PEG and PE to render this moiety pH-sheddable. After the nano-
carriers reach tumors by the help of the mAb-conjugated PEG, the long PEG chains are 
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shed due to the hydrolysis of the acid-sensitive hydrazone bond, exposing the Tat-
conjugated PEG, which can then improve the internalization of the nano-carriers into 
tumor cells [205;207]. In a recent study, Zhu et al. applied the idea of hydrazone-based 
PEG-shedding to actively target TAMs [211]. The nanoparticles are composed of PLGA 
core (with 5% PLGA-FITC), stearoyl-mannose (C18-mannose), and PEG-hydrazone-
stearoyl (PEG-hydrazone-C18, PHC). The stearoyl moiety in both PHC and C18-
mannose are expected to be inserted into the lipophilic PLGA core, leaving the short 
mannose and the long PEG moieties projecting outwardly. Once the long-circulating 
nanoparticles accumulate in the tumor via EPR, the PEG chains are shed in the acidic 
tumor environment (pH 6.8), bringing the mannose moiety to the front, which enables the 
nanoparticles to interact with TAMs via mannose-mannose receptor interaction [211]. In 
contrast, nanoparticle uptake by normal macrophages at physiological pH is hindered by 
the shielding effect of the PEG chains [211]. This formulation provided a successful tool 
for the active targeting of TAMs. 
Using PEG-shedding to expose another hidden surface targeting ligand can take 
place via other mechanisms as well.  For example, Torchilin’s group designed an MMP2-
sensitive micellar formulation that sheds PEG chains and exposes a cell penetrating Tat-
peptide once the micelles reach the MMP2-rich tumor microenvironment [212]. The shed 
PEG chains, which are connected to the MMP sensitive peptide, are long (2 kDa) to 
provide extended plasma circulation of the micelle formulation, while the Tat-peptide-
conjugated PEG chains are shorter (1kDa) to keep the Tat shielded until the micelles 
reach tumor microenvironment. Paclitaxel, conjugated to the MMP-sensitive PEGylated 
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moiety, remained at the core of the Tat-peptide decorated micelle structure due to its 
lipophilic nature [212].  
 
1.4.3 Cellular Barriers. 
 
1.4.3.1 Nano-carrier internalization by cancer cell and endosomal escape. 
Once the nano-carrier gets past all the previously mentioned barriers, it comes in 
contact with the tumor cells and starts to interact with tumor cell membrane to get 
internalized (endocytosis). The process of endocytosis starts with invagination of the 
nano-carriers into the cell, forming a specific vesicle (endosome or phagosome), in which 
the nano-carriers are entrapped. Five major endocytic pathways for the internalization of 
nano-carriers have been identified, namely phagocytosis, macropinocytosis, clathrin-
mediated endocytosis, caveolin-mediated endocytosis, and clathrin/caveolin-independent 
endocytosis [120;213;214]. The type of endocytosis depends on several factors, including 
nano-carrier size, surface chemistry and ligands, and the tumor cells [120]. Caveolin and 
clathrin are proteins assisting the endosome formation and the endocytosis process. The 
pH inside several internalized vesicles is usually acidic, with various values. Both 
clathrin-mediated and caveolin-mediated endocytosis form early endosomes (pH 6.5-6.8), 
which become late endosomes (pH 5.2-6.2), while phagocytosis and macropinocytosis 
form phagosomes and macropinosomes, respectively. All three vesicles deliver their 
cargos to lysosomes (pH 4.5-5.2) [213]. Both the acidic conditions and the presence of 
hydrolytic enzymes facilitate the digestion of the internalized cargos and destroy them. 
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Thus, it is important that the nano-carriers find a way out of the endosomes before 
reaching the terminal lysosomes [215]. Among the methods adopted to enable the 
endosomal escape of nano-carriers from the endosomes is the proton-sponge effect 
method, where nano-carriers with secondary or tertiary amine groups (e.g., poly-L-
histidine, polyethylene imine (PEI), or chitosan) are protonated by the acidic pH inside, 
which results in the extensive flow of ions and water inside the endosomes, resulting in 
osmotic swelling and subsequent rupture of the lysosomes. The nano-carriers then escape 
into the cytosol [215;216]. Other endosomal escape mechanisms include the use of 
fusogenic peptides (e.g., influenza HA2 peptide and GALA peptide) that destabilize the 
endosomal membrane after some acid-sensitive conformational changes of their 
structures take place[217;218].  
In one example, nevertheless, it seems like what comprises a ‘curse’ to some 
nano-carriers turns out to be a ‘blessing’ to others. Wonganan et al. found that the 
GemC18-SLNs are taken up by tumor cells by clathrin-mediated endocytosis, and the 
gemcitabine is liberated in lysosomes due to acid-sensitive hydrolysis  and lysosomal 
enzymes such as cathepsins [219]. Free gemcitabine is then likely exported out of the 
lysosomes by human equilibrative nucleoside transporter-3 (hENT-3) in the lysosomal 
membrane. It seems that, following this pathway, the liberated gemcitabine is shuttled 
into a natural ‘salvage’ pathway that cells adopt to recycle endogenous (e.g., apoptotic 
bodies) or exogenous DNA (e.g., DNA from bacteria or viruses), and is phosphorylated 
more efficiently into the active difluoro-deoxycytidine triphosphate (dFdCTP) to inhibit 
cell growth [219]. In this case, functional lysosomes are critical to efficiently generate 
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dFdCTP, as alkalinization of lysosomes with ammonium chloride significantly inhibits 
the cytotoxic action of GemC18-SLNs [219]. In contrast, the GemC18 diffuses inside 
tumor cells very rapidly and is hydrolyzed quickly into free gemcitabine. However, it 
appears that the gemcitabine that reaches cell cytosol following this pathway cannot be 
efficiently phosphorylated into its active dFdCTP. Gemcitabine alone can be effectively 
taken up by cells via nucleoside transporters such as hENT-1 located in the cell 
membrane. However, it is extensively deactivated into its inactive dFdU derivative before 
being phosphorylated [219]. For a more detailed description of this example, the reader is 
referred to ([219]) 
  
1.4.3.2 ATP-binding cassette transporters (ABC transporter, efflux transporter-
mediated resistance)  
ABC transporters are a family of proteins that include multidrug resistance 
protein-1 (MDR-1) and P-glycoprotein (P-gp) [138]. Human P-gp, a 170 kDa trans-
membrane glycoprotein, is composed of 12 hydrophobic domains and 2 nucleotide 
domains [220], and is a major component of the blood brain barrier [221]. It can transport 
several small molecules, either from the cytosol or from the cell membrane, out of the 
cell, which  significantly reduces cellular accumulation of cytotoxic molecules [138;222]. 
The mere use of a nano-carrier to deliver the chemotherapeutic agents intracellularly had 
been shown to overcome the P-gp-mediated efflux [223], as the nano-carrier is not a 
substrate to the protein. Additionally, several nano-carrier based approaches, including 
the concomitant use of efflux inhibitors (e.g., cepharanthine [224] and tariquidar [225]), 
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silencing the gene encoding P-gp [226;227], and the use of certain excipients and 
surfactants (e.g., poloxamers and tocopheryl-polyethylene glycol succinate (TPGS) 
[228;229]), are among the strategies that have been explored to reverse ABC transporter-
mediated multi-drug resistance to nanomedicine. 
For example, Panyam and co-workers developed a biotin-functionalized PLGA 
nanoparticles that encapsulate a dual drug payload of paclitaxel and the third generation 
P-gp inhibitor tariquidar to target the biotin receptors overexpressed by tumor cells [225]. 
Within a concentration range at which neither paclitaxel in solution or in nanoparticles 
was effective, tariquidar enhanced the cytotoxic effect of paclitaxel, both in solution and 
in nanoparticles, in chemoresistant cell lines that overexpress P-gp. Furthermore, the 2 h-
cellular uptake of paclitaxel was the greatest when tariquidar was co-encapsulated with 
paclitaxel in PLGA nanoparticles. The authors attributed the lack of activity of paclitaxel 
nanoparticles in these cell lines to the overexpressed P-gp, as the slowly released 
paclitaxel is readily removed by P-gp. However, the simultaneous slow release of 
tariquidar inhibited P-gp and accordingly enhanced the accumulation of the slowly 
released paclitaxel. The dual agent encapsulation in the biotin-functionalized 
nanoparticles significantly enhanced the antitumor activity and survival in mice bearing 
resistant tumors [225]. The same group also showed that simultaneous encapsulation, and 
subsequent intracellular co-localization, of paclitaxel and a P-gp-silencing siRNA can 
successfully enhance the anticancer activity of paclitaxel in resistant cells [230]. Using a 
different modality, Navarro et al. showed that the pretreatment of resistant breast cancer 
cells with siRNA, loaded on a cationic PEI-functionalized phospholipid-based nano-
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carrier, can significantly enhance the cytotoxic activity of a subsequent treatment with 
doxorubicin solution [226]. Other cellular-mediated ABC transporter-independent 
resistance mechanisms to chemotherapy include apoptosis inhibition and DNA repair 
modification [205]. For example, survivin is an antiapoptotic protein that is 
overexpressed in cancer cells. and the silencing of survivin gene expression has been 
identified as a successful tool to overcome drug resistance in cancer cells [231;232]. 
Yang et al. functionalized the polysaccharide chitosan with a cell penetrating peptide and 
utilized it to deliver survivin siRNA [233]. The siRNA-chitosan complexes effectively 
induced apoptosis in cancer cells and inhibited the tumor growth in mice with orthotopic 
mammary tumors, while the naked siRNA was not effective [233]. For deeper insights on 
the use of nanomedicine to overcome cellular-mediated drug resistance mechanisms in 
tumors, the reader can refer to [138;205;221;234;235].    
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1.5 Conclusion 
       Nanomedicine opens a totally different horizon in cancer chemotherapy, with so 
many opportunities waiting. However, as more opportunities come in the way, more 
challenges are also revealed. More efforts are needed to fully take advantage of its 
potentials. 
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Chapter 2 
Solid lipid nanoparticle formulations of docetaxel prepared with high-melting point 
triglycerides: in vitro and in vivo evaluation 2 
 
2.1 Introduction 
Docetaxel (DCX) is a second generation taxane, derived from the inactive 10-
deacetyl baccatin III, extracted from the European Yew tree (Taxus baccata) [236;237]. 
DCX has better water solubility, pharmacokinetic profile, and anticancer activity than 
paclitaxel [236;238]. Current FDA approved DCX products, including Taxotere®, are 
essentially Tween 80/ethanol-based solutions [239], which unfortunately are associated 
with various significant side effects. They induce marked hypersensitivity, neutropenia, 
fluid retention, and alopecia [239-241]. Hypersensitivity reactions, which are attributed to 
the Tween 80 in the formulations, vary from simple skin rash to systemic anaphylaxis 
[239;242], and necessitate premedication with corticosteroids [243]. Other problems 
associated with the Tween 80/ethanol-based DCX formulations include the non-specific 
accumulation of DCX in healthy organs, which may lead to systemic toxicity and 
subsequent discontinuation of therapy [86].  
Nanoparticle-based, Tween 80-free DCX formulations are expected to not only 
avoid Tween 80-related side effects, but also increase the concentration of DCX in 
tumors due to the enhanced permeation and retention (EPR) effect [86;88;239].  
  
 
 
2 This chapter is based on “Youssef W. Naguib, B. Leticia Rodriguez, Xinran Li, Stephen D. Hursting, Robert 
O. Williams, and Zhengrong Cui, Molecular Pharmaceutics, 2014, 11(4): 1239-1249” 
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Data from many previous studies show that nanoparticles of 100-200 nm are the 
most successful in tumor vasculature extravasation [31;120], although there are 
disagreements in the literature [88;91;109;244-246]. The heterogeneous nature of tumor 
type, size, location, and metastasis may contribute to the disagreements [94]. In order to 
improve the EPR-related nanoparticles extravasation, nanoparticles should be designed to 
circulate longer in the blood, while the drug of interest is retained within the 
nanoparticles [44]. PEGylation is a strategy to render the surface of nanoparticles 
hydrophilic, which enables the nanoparticles to evade early opsonization and circulate 
longer in the blood [125;247]. On the other hand, for a drug to be retained within the 
nanoparticles, a strong affinity between the drug and the excipient(s) used to prepare the 
nanoparticles is required [44]. 
Solid lipid nanoparticles (SLNs) have been extensively investigated as drug 
carriers [42;248-250]. Advantages of such nano-carriers include high compatibility with 
lipophilic drugs, ease of fabrication, and controlled release [37;42;44;250]. Various SLN 
formulations of taxanes have been previously reported [38;251-253]. Heurtault et al. 
reported the development of a PEGylated lipid nano-capsule formulation (LNCs) for 
paclitaxel using a novel phase inversion-based method [254]. The resultant LNCs were 
made of an oily medium-chain triglyceride core and stabilized with soybean lecithin as a 
lipophilic surfactant, and PEG hydroxystearate (Solutol®) as a hydrophilic surfactant 
[254-256]. Lee et al. applied a high pressure homogenization technique to prepare a SLN 
formulation of paclitaxel using triglyceryl myristate (trimyristin) and phospholipids 
[253]. The formulation showed improved in vitro activity [253], but the in vivo 
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circulation time and biodistribution profile were not improved, as compared to the market 
product Taxol® [257]. Videira et al. applied a factorial design to optimize formulation 
parameters to prepare paclitaxel SLN formulations using Compritol 888 ATO® (a 
mixture of mono-, di-, and triglycerides of behenic acid) and Precirol ATO5® (i.e., 
glyceryl palmito-stearate), and the final optimized formulation exhibited improved in 
vitro cytotoxic activity against the murine breast cancer cell line MXT-B2 [258].  
The present study aimed at the rational selection of a triglyceride from a list of 
medium- and long-chain triglycerides for the development of a SLN formulation to 
ultimately improve the antitumor activity of DCX. Previously it was reported that low 
melting point triglycerides are excellent solubilizers for DCX [259], prompting us to 
hypothesize that high melting point triglycerides will be suitable excipients for preparing 
DCX-incorporated SLNs. Triglycerides that are solid at body temperature were selected 
to ensure formulation stability and to avoid droplet coalescence [253]. An oil-in-water 
(O/W) emulsion-based method was applied, where DCX and all lipid components were 
dissolved in the oil phase, and the aqueous phase consisted of a 0.1% (w/v) Poloxamer 
188 aqueous solution. Finally, the in vitro and in vivo antitumor activities of the selected 
formulation were evaluated.  
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2.2 Materials and Methods 
 
2.2.1 Materials 
DCX was from LC Laboratories (Woburn, MA, USA). The 1,2-dioleoyl-sn-
glycero-3-phosphoethanoamine-N-[methoxy (polyethylene glycol)-2000] (DOPE-PEG-
2000) and phosphatidylcholine from chicken egg (ePC) were from Avanti Polar Lipids, 
Inc. (Alabaster, AL, USA). Sepharose® 4B, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) kit, Tween 80 (T80), Poloxamer 188 (Pluronic F68®), 
trimyristin (TM), trilaurin (TL), tristearin (TS), tripalmitin (TP), mannitol, sucrose, 
phosphate buffer saline (PBS, pH 7.4), triglyceride assay kit, and caspase 3 assay kit were 
all from Sigma-Aldrich (St. Louis, MO, USA). Float-A-Lyzer dialysis tubes (MWCO 
50,000) were from Spectrum Chemicals & Laboratory Products (New Brunswick, NJ, 
USA).  
 
2.2.2 Cell lines and animals 
            TC-1 cells (murine lung cancer cell line) were from the American Type Culture 
Collection (ATCC, Rockville, MD, USA) and grown in RPMI 1640, supplemented with 
10% fetal bovine serum (FBS) and 1% of 100 g/ml streptomycin and 100 IU/ml 
penicillin (1% P/S). M-Wnt cells (murine mammary gland cell lines) were from Dr. 
Stephen D. Hursting’s lab at The University of Texas at Austin. M-Wnt cells were grown 
in a similar medium as TC-1, with an additional supplement of 1% Glutamax®. Human 
breast adenocarcinoma cells (MDA-MB-231) were from ATCC and grown in DMEM 
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supplemented with 5% FBS and 1% P/S. All cell culture reagents were from InvitrogenTM 
(Life Technologies, Carlsbad, CA, USA). Female C57BL/6 mice (6-8 weeks old) were 
from Charles River Laboratories (Wilmington, MA, USA).  
 
2.2.3 Preparation of SLNs 
            SLNs were prepared using a modified emulsion/solvent evaporation method. 
Briefly, 1 ml of dichloromethane (DCM) containing DCX, a triglyceride (TM, TP, TL, or 
TS), egg PC, and DOPE-PEG-2000 in a weight ratio of 1:20:10:2 was added to 10 ml of 
0.1% Poloxamer 188 aqueous solution in a glass vial, and the mixture was sonicated 
using a probe sonicator, with a micro-probe attached, for 40 s, at a sonication intensity of 
50% (Q-sonica LLC, Newtown, CT, USA). The glass vial was placed in an ice bath 
during sonication to prevent heat accumulation. The emulsion was stirred for 15 min at 
400 rpm in a water bath (65° C) to evaporate DCM, and was then stirred for 1 hour at 
room temperature. The resultant nanoparticle suspension was concentrated to 1 ml by 
ultrafiltration using an Amicon® device (Millipore Inc., 30,000 MWCO) (490 x g, 25 
min, 4°C) as previously reported [260]. Finally, SLNs were briefly sonicated to eliminate 
aggregates due to the concentration process. DCX-free SLNs were prepared similarly 
without the addition of DCX. For SLNs that were used in animal studies, the 
ultrafiltration period was extended to 60 min to further concentrate the suspension. The 
prolonged ultrafiltration did not result in any significant particle size change (data not 
shown). SLNs were lyophilized using a Freezone freeze dryer (Labconco Corp., Kansas 
City, MO, USA) with 9.25% (w/v) sucrose as a cryoprotectant. The Tween 80/ethanol-
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based DCX formulation (DCX in T80/E) was prepared by dissolving DCX in Tween 80 
(20 mg/ml). This concentrate was then diluted with water/ethanol solution to make a final 
DCX solution of 4 mg/ml. The final concentrations of Tween 80 and ethanol in the 
solution were 20% (v/v) and 13% (v/v), respectively. 
 
2.2.4 Determination of particle size and zeta potential 
            Particle size and zeta potential of the SLNs were measured using a Malvern 
Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Briefly, 20 l of the 
concentrated SLNs in suspension were diluted to 1 ml with water, and the particle size 
and zeta potential were determined at room temperature.     
 
2.2.5 Transmission electron microscopy (TEM)    
             The SLNs were examined using an FEI Tecnai Transmission Electron 
Microscope (FEI Corporate, OR, USA) at the Institute for Cellular and Molecular 
Biology, Microscopy and Imaging Facility at The University of Texas at Austin as 
previously reported [208]. 
 
2.2.6 Determination of DCX content and loading percentage in the SLNs 
            The content of DCX in the SLNs was determined using HPLC after extraction as 
previously reported with modifications [253]. Briefly, SLNs in suspension were diluted 
5-10 times with methanol in a glass vial, which was placed in a water bath (65°C) for 20 
min to dissolve the lipids, and placed at -20°C for 45 min. The supernatant was collected 
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by centrifugation at 18,000 g for 10 min at 4°C (Beckman Coulter Inc., Brea, CA, USA), 
and 5 l of the supernatant was used for HPLC assay as previously described [210]. The 
HPLC system consisted of an Agilent HPLC workstation (Agilent Corp., Santa Clara, 
CA, USA), with RP-C18 column (Zorbax Eclipse, 5 m, 4.6 mm × 150 mm; Santa Clara, 
CA, USA). The mobile phase was acetonitrile and water (1:1, v/v). The flow rate was 1 
ml/min, and the detection wavelength was 230 nm. The DCX loading percentage was 
measured using a similar procedure, with the exception of that the SLNs were 
lyophilized, and 5 ml of methanol were added to 5 mg of the lyophilized SLNs. The 
weight percentage of DCX in the SLNs (% w/w) was calculated based on the following 
formula [261]: 
 
100
)(
)(% 
mgweightSLNs
mgweightDCXloadingDrug                     Equation 1 
 
2.2.7 Gel permeation chromatography (GPC) 
            To investigate whether free DCX coexisted with DCX-SLNs in the nanoparticle 
preparation, the SLNs (100 µl) were applied to a Sepharose® 4B column (6 mm x 30 cm) 
equilibrated with water, and the DCX-SLNs were eluted with water. Fractions of 0.5 ml 
were collected, and 0.3 ml of each fraction was lyophilized to determine the content of 
DCX as mentioned above. In addition, the absorbance of each fraction (100 l) at 500 nm 
was measured using a BioTek SynergyTM HT Multi-Mode Microplate Reader (Winooski, 
VT, USA) to determine their turbidity, which was used as an indication of the presence of 
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nanoparticles in the fractions collected. Finally, the concentration of triglycerides in each 
fraction was also measured using a Sigma Triglyceride Assay Kit following the 
manufacturer’s instruction.  
 
2.2.8 Short-term stability study 
            DCX-SLNs prepared using different triglycerides were stored in parafilm-sealed 
vials at 4°C for eight days. Particle size, zeta potential, and DCX content were measured 
as mentioned above shortly after the preparation and on day 8 to monitor any change of 
these parameters.  
 
2.2.9 In vitro release of DCX from the SLNs 
            The release of DCX from the SLNs made with different triglycerides was 
monitored using Float-A-Lyzer tubes (MWCO 50,000). Briefly, DCX-SLNs suspension 
was diluted to 1 ml with PBS and transferred to the dialysis tube, which was then placed 
in a 50 ml plastic tube containing 20 ml of release medium (PBS, 0.1 mM, pH7.4, with 
1% Tween 80). The tubes were then placed at 37°C in an orbital shaker at 100 rpm (Max-
Q 5000, Thermo Scientific, Waltham, MA, USA). At predetermined time points, the 
whole release medium was replaced with fresh medium to maintain sink condition, and 
DCX concentration was analyzed using HPLC as previously mentioned. The release of 
DCX from the DCX in T80/E formulation was evaluated similarly for comparison.    
 
2.2.10 Modulated differential scanning calorimetry (mDSC) 
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            For mDSC, a TA Instruments Model 2920 DSC (New Castle, DE, USA) was 
used, and the data were analyzed using TA Universal Analysis 2000 Software. 
Accurately weighed samples were placed in aluminum crimped pans. The ramp rate was 
5°C/min, and the temperature range was from 10° C to 200° C. The modulation 
amplitude and period were 0.5°C and 40 s, respectively. Ultra high purity nitrogen was 
flowing through the sample chamber during the run. Samples included DCX, trimyristin, 
DCX-SLNs (prepared with trimyristin), blank SLNs, and the physical mixture of DCX 
and blank SLNs.  
 
2.2.11 X-Ray Diffraction (XRD) 
            A Philips Model 1710 X-ray diffractometer (Philips Electronic Instruments Inc., 
Mahwah, NJ, USA) available in the Texas Materials Institute X-ray Facility at The 
University of Texas at Austin was used to analyze the crystallinity of DCX in the SLNs. 
Samples included DCX alone, DCX-SLNs (prepared with trimyristin), DCX mixed with 
blank SLNs, and blank SLNs.  
 
2.2.12 Cell proliferation assay 
            Cells were seeded in 96-well plates at a density of 3,000 cells/well and incubated 
at 37°C with 5% CO2 overnight. They were treated with various concentrations of DCX-
SLNs (prepared with trimyristin), DCX in T80/E, Blank SLNs, or T80/E alone for 72 h. 
Cell viability was determined using an MTT assay as previously described [210].  IC50 
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values were calculated using GraphPad prism (GraphPad software, Inc., La Jolla, CA, 
USA). 
 
2.2.13 Caspase 3 activity assay 
            Caspase 3 activity was determined using a Sigma-Aldrich Caspase 3 Fluorimetric 
Assay Kit. In brief, TC-1 cells were seeded in 24 well-plates at 25,000 cells/well and 
incubated overnight. The cells were treated with DCX-SLNs (prepared with trimyristin), 
DCX in T80/E, Blank SLNs, or T80/E for 72 h. The concentration of the DCX was 0.01 
M. The cells were then washed with PBS and lysed. The cell lysate was centrifuged at 
18,000 g for 10 min at 4°C. The supernatant was transferred to a clear-bottomed black 
plate and mixed with the assay substrate, acetyl-Asp-Glu-Val-Asp-7-amido-4-
methylcourmarin (Ac-DEVD-AMC). The mixture was incubated for 6 h for the 
hydrolysis of the Ac-DEVD-AMC by caspase 3 to release the ﬂuorescent AMC, which 
was quantiﬁed by measuring the ﬂuorescence intensity at 360 nm (excitation)/460 nm 
(emission) according to the manufacturer's instruction. The unit of the caspase 3 activity 
was mol AMC/min/ml. A caspase 3 inhibitor (provided in the kit) was used to confirm 
that the fluorescence was due to caspase 3 activity. Total protein concentration in the cell 
lysates was determined using Bio-Rad DC® Protein Assay Kit following the 
manufacturer’s instruction. 
 
2.2.14 Evaluation of the antitumor activity of the DCX-SLNs in vivo 
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All animal protocols were approved by the Institutional Animal Care and Use 
Committee at the University of Texas at Austin, and the National Institutes of Health 
(NIH) guidelines for laboratory animal use and care were followed. Animals were left to 
acclimatize for at least 7 days upon arrival from the vendor. Each mouse was injected 
with the murine TC-1 lung cancer cells (5 x 105 cells per mouse) suspended in 100 l of 
FBS-free RPMI 1640 medium subcutaneously in the shaved left flank. Six days after the 
implantation (day 6), mice were randomized into 4 groups, 7 mice per group, and injected 
intravenously via the tail vein with DCX-SLNs (prepared with trimyristin), DCX in 
T80/E, Blank SLNs, or 5% mannitol as a vehicle control. The dose of DCX was 15 
mg/kg body weight. Mannitol was used to adjust the tonicity of the nanoparticle 
suspension. Injection was repeated on days 9 and 12 post-implantation. Tumor sizes were 
measured using a digital caliper, and tumor volumes were calculated using the following 
formula [39]: 
5.0)]()()([)( 3  mmWidthmmWidthmmLengthmmvolumeTumor         Equation 2 
            On day 21, mice were euthanized to harvest tumor tissues, which were weighed, 
fixed in Zn formalin buffer for immunohistochemistry.  
 
2.2.15 Immunohistochemistry 
            Tissue sample preparation for immunohistochemical evaluation was carried out in 
the Histology and Tissue Analysis Core at Dell Pediatric Research Institute (DPRI) at 
The University of Texas at Austin. The formalin-fixed tumor tissues were embedded in 
paraffin wax, sectioned, and stained with an antibody against CD-31 (Abcam, 
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Cambridge, MA, USA) as a marker for angiogenesis (n = 3) [39]. Slides were then 
scanned, and images were taken using the ScanScope XT (Aperio Technologies, Vista, 
CA, USA).  
 
2.2.16 Biodistribution and tumor uptake 
            TC-1 tumors were implanted in female C57BL/6 mice as mentioned above. Three 
weeks after tumor implantation, mice were divided into 2 groups (n = 9-10); one group 
was injected with DCX in T80/E (equivalent to DCX dose of 16 mg/kg) via the tail vein, 
and the other group with DCX-SLNs prepared with trimyristin (equivalent to DCX dose 
of 16 mg/kg). Two or twelve hours later, 4-5 mice from each group were euthanized to 
collect tumor, liver, kidney, spleen, heart, lung, and blood samples. The organs and tumor 
tissues were weighed, and stored at -80o C. The blood samples were mixed with an EDTA 
solution and allowed to stand for about 15 min and centrifuged (3300 g, 10 min, 4° C) to 
separate the plasma, which was stored at -80o C. DCX was extracted from the samples 
using ethyl acetate, and DCX concentrations in the samples were determined using 
HPLC. Paclitaxel was used as an internal standard.  
 
2.2.17 Statistical analyses 
            Statistical analyses were completed by performing ANOVA followed by Fisher’s 
protected least signiﬁcant difference procedure. A p-value of ≤ 0.05 (two-tail) was 
considered signiﬁcant. 
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2.3 Results  
 
2.3.1 Preparation of DCX-SLNs and selection of triglyceride in the SLNs 
SLNs were prepared using a modified emulsion/solvent evaporation method. The 
nanoparticles were composed of DCX, a triglyceride, ePC, DOPE-PEG-2000, and 
Pluronic F68. The average particle size of SLNs produced using tristearin, tripalmitin, 
trimyristin, and trilaurin, as the triglyceride was 178.4 ± 2.3, 176.3 ± 3.9, 182.8 ± 2.0, and 
150.7 ± 14.5 nm, respectively (Table 2.1). The polydispersity indices of all nanoparticle 
preparations were equal to, or below, 0.2. The zeta potential of the SLNs was 
approximately -30 mV. The content of DCX in the final SLNs was 2.4-2.8% (w/w) 
(Table 2.1). 
            The release profiles of DCX are shown in Figure 2.1. The release of DCX from 
the SLNs was slower, relative to the diffusion of DCX out of the DCX in T80/E 
formulation (Figure 2.1A). Only about 4.5-9% of the DCX was released from the SLNs 
formulation within the first 6 h, whereas about 31% of DCX diffused out of the T80/E 
formulation within the same time period (Figure 2.1A). The rate at which the DCX was 
released from the DCX-SLNs prepared with trimyristin was the slowest (Figure 2.1B).  
            During a short-term, 8-day stability study at 4°C, no significant change in particle 
size and DCX content in any of the four DCX-SLNs preparations was found (Figure 
2.2A-B). However, the zeta potential of DCX-SLNs prepared with tripalmitin and 
trilaurin changed significantly (Figure 2.2C). Based on data shown in Figures 2.1 and 2.2, 
the DCX-SLNs prepared with trimyristin were chosen for further studies, because the 
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release of DCX from the SLNs prepared with trimyrstin as the triglyceride was the 
slowest, and the resultant DCX-SLNs were also relatively more stable. 
 
2.3.2 Characterization of DCX-SLNs prepared with trimyristin as the triglyceride  
            Shown in Figure 2.3A are the GPC results for the DCX-SLNs prepared with 
trimyristin as the triglyceride. About 90% of the DCX that was eluted from the column 
was associated with the triglyceride and with the fraction that contained the nanoparticles 
(calculated based on the area under curves of the GPC profiles) (Figure 2.3A). TEM 
showed that the DCX-SLNs are spherical (Figure 2.3B). The SLNs were successfully 
lyophilized with 9.25% (w/v) sucrose as a cryoprotectant (data not shown).  
            DSC analysis of the DCX-SLNs, free DCX, blank SLNs, and blank SLNs mixed 
with DCX showed that DCX exhibited a characteristic melting peak at 167.4o C (Figure 
2.4A). The physical mixture exhibited an endothermic melting peak at 143.4o C, which 
can be attributed to the presence of free DCX, as the blank SLNs did not show any 
distinct peak at that temperature. A characteristic DCX endothermic melting peak was 
also absent in the DCX-SLNs (Figure 2.4A). On the other hand, the presence of the 
endothermic melting peak of trimyristin at approximately 55-58o C confirmed the solid 
state of the lipid within the SLNs (Figure 2.4A). Finally, XRD showed that a 
characteristic DCX peak was present in the physical mixture, but absent in the DCX-SLN 
composition (Figure 2.4B).   
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Table 2.1: Physical parameters of DCX-SLNs prepared with different triglyerides. 
Data shown are mean ± S.D. (n = 3). 
SLNs Triglyceride 
Particle size 
(nm) 
Polydispersity 
index 
Zeta 
potential 
(mV) 
DCX 
loading 
(%, w/w) 
TS Tristearin 178.4 ± 2.3 0.181 -29.6 ± 2.3 2.6 ± 0.2 
TP Tripalmitin 176.3 ± 3.9 0.162 -30.7 ± 2.8 2.8 ± 0.1 
TM Trimyristin 182.8 ± 2.0 0.196 -29.8 ± 1.8 2.4 ± 0.1 
TL Trilaurin 150.7 ± 14.5 0.165 -29.3 ± 1.5 2.5 ± 0.1 
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Figure 2.1: (A) The release of DCX from DCX-SLNs (closed circles) prepared using 
tristearin (TS), tripalmitin (TP), trimyristin (TM), or trilaurin (TL). As a control, the 
release of DCX from DCX in T80/E (open circles) was also included. Each point 
represents mean ± S.D. from three independent measurements. (B) A comparison of the 
percent of DCX released per hour from DCX-SLNs prepared using different 
triglycerides. The release rates were calculated with data in the initial 24 h period. Each 
point represents mean (n = 3). 
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Figure 2.2: Stability of the DCX-SLNs formulations prepared using different 
triglycerides. The particle sizes (A), DCX contents (B), and zeta potentials (C) of DCX-
SLNs prepared with different triglycerides shortly after preparation or after 8 days of 
storage at 4°C. Data shown are mean ± S.D. (n = 3). 
 61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure: 2.3 
 62 
Figure 2.3: Gel permeations chromatogram of the prepared DCX-SLNs (prepared 
using trimyristin) and a representative TEM image of DCX-SLNs. (A) A 
representative GPC profile of DCX-SLNs prepared with trimyristin. Collected fractions 
were divided into three portions; one was analyzed for DCX content (red), one was used 
to measure turbidity (OD 500 nm) (blue), and the other one was used to measure 
trimyristin concentrations, and the visible absorbance of the formed colored component 
was measured (OD 540) (black). This experiment was repeated three times with similar 
results. (B) A representative TEM image of DCX-SLNs prepared with trimyristin (bar = 
200nm).
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Figure 2.4: Physicochemical characterization of DCX-SLNs. DSC thermograms (A) 
and X-ray diffractograms (B) of DCX-SLNs, DCX alone, trimyristin (TM) alone, blank 
SLNs, or the physical mixture of blank SLNs and DCX. 
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2.3.3 Cytotoxicity of the DCX-SLNs prepared with trimyristin as a triglyceride 
against tumor cells in culture 
MTT assay revealed that both DCX-SLNs and DCX in T80/E inhibited the 
proliferation of tumor cells, including murine mammary gland cancer cells (M-Wnt), 
murine lung cancer cells (TC-1), and human breast adenocarcinoma cells (MDA-MB-
231). However, the IC50 values of the DCX-SLNs were significantly lower than that of 
the DCX in T80/E in each of the three cell lines (Figure 2.5A). At the highest equivalent 
DCX concentrations tested (i.e., 0.01, 1, and 0.05 µM in M-Wnt, TC-1, and MDA-MB-
231, respectively), both the blank SLNs and the T80/E vehicle control did not show any 
significant toxicity in all three cell lines (data not shown).  
            Caspase 3 activity was also measured in TC-1 cells treated with DCX-SLNs, 
DCX in T80/E, Blank SLNs, and T80/E at a DCX concentration of 0.01 µM. Caspase 3 
activity in cells treated with the DCX-SLNs was significantly higher than in cells treated 
with DCX in T80/E (p < 0.005, Figure 2.5B). The total protein contents in the cell lysates 
in all four groups were not significantly different (data not shown).     
 
2.3.4 The antitumor activity of the DCX-SLNs prepared with trimyristin as a 
triglyceride in a mouse model 
 The antitumor activity of DCX-SLNs was evaluated in TC-1 murine lung cancer 
tumor model pre-established in C57BL/6 mice. As shown in Figure 2.6A, both DCX-
SLNs and DCX in T80/E significantly inhibited the growth of the TC-1 tumors in mice. 
However, the DCX-SLNs were significantly more effective than the DCX in T80/E 
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formulation, starting on day 15 (Figure 2.6A). The average body weights of mice that 
were injected with blank SLNs or 5% mannitol (as a vehicle control) increased slightly 
(~10%) during the 21 days after tumor cells implantation, while the average body weight 
of mice that were treated with DCX-SLNs or DCX in T80/E did not show any significant 
change (Figure 2.6B). Finally, the average weight of tumors in mice that were treated 
with the DCX-SLNs was also significantly lower than that in other groups at the end of 
the study (Figure 2.6C). Anti-CD31 staining (i.e., angiogenesis marker) showed that the 
extent of CD31+ staining tended to be lower in tumors in mice that were treated with the 
DCX-SLNs, as compared to in other groups (Figure 2.6D). 
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Figure 2.5: Apoptotic and anti-proliferative activity of the DCX-SLNs. (A) The IC50 
values of DCX-SLNs and DCX in T80/E in MDA-MB-231, M-Wnt, and TC-1 cells. 
Cells were incubated with the DCX formulations for 72 h. (B) Caspase 3 activity (in 
mmol AMC/min/ml) in TC-1 cells following 72 h of incubation with DCX-SLNs or DCX 
in T80/E (DCX, 0.01 µM). Controls include blank SLNs, T80/E vehicle, or medium 
alone. Data shown are mean ± S.D. (n = 4).
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Figure 2.6: Antitumor activity of DCX-SLNs in tumor-bearing mice. (A) The growth 
curves of TC-1 tumors in C57BL/6 mice (a p < 0.05, DCX-SLNs or DCX in T80/E vs. 
5% mannitol, b p < 0.05, DCX-SLNs vs. DCX in T80/E). (B) The changes in the body 
weight of TC-1 tumor-bearing mice. (C) The weights of tumors at the end of the study. 
(D) Representative images of tumor tissues after anti-CD31 staining (Bar = 100 µm). 
Mice were i.v. injected with DCX-SLNs or DCX in T80/E at a DCX dose of 15 mg/kg 
via the tail vein on days 6, 9, and 12 after tumor implantation. Controls included mice 
that were injected with blank SLNs or 5% mannitol. Data shown in A-C are mean ± 
S.E.M. (n = 7).
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2.3.5 Biodistribution study 
            Figure 2.7 shows the concentration of DCX in tumors and other organs in TC-1 
tumor-bearing mice 2 and 12 h after the mice were injected intravenously with either 
DCX-SLNs (prepared with trimyristin) or DCX in T80/Ethanol. The concentration of 
DCX in tumors in mice that were injected with DCX-SLNs was about 50% higher than in 
mice that were injected with the DCX in T80/Ethanol formulation, 12 h after the injection 
(p < 0.05) (Figure 2.7A). However, the concentration of DCX in the liver, spleen, 
kidneys, heart, and lungs of mice injected with the DCX-SLNs were lower than in mice 
injected with the DCX in T80/E formulation (Figs. 7B-F). Finally, 2 h after intravenous 
injection, the concentration of DCX in the plasma in mice that were injected with the 
DCX-SLNs was about 5-times higher than in mice that were injected with the DCX in 
T80/E formulation (Figure 2.7G).     
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Figure 2.7: Biodistribution profile of DCX-SLNs in the tumors and organs of mice. 
The concentrations of DCX in tumor (A), liver (B), lungs (C), heart (D), kidneys (E), 
spleen (F), and plasma (G) of TC-1 tumor-bearing C57BL/6 mice 2 or 12 h after i.v. 
injection of either DCX-SLNs or DCX in T80/E. The dose of DCX was 16 mg/kg. Data 
shown are mean ± S.E.M. (n = 4-5). 
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2.4 Discussion  
            Since the discovery of taxanes in the mid-1980s, the fervent search for more 
efficacious and less toxic taxane formulations has led to the FDA approval of three 
market products, namely Taxol® (Bristol-Myers Squibb, Princeton, NJ, USA), Taxotere® 
(Sanofi-Aventis U.S. LLC, Bridgewater, NJ, USA), and Abraxane® (Celgene 
Corporation, Summit, NJ, USA). In addition, a polymeric PEGylated micelle formulation 
of paclitaxel (Genexol-PM) has been marketed in South Korea since 2007 [262-264], and 
others (e.g. BIND-014) are in the pipeline [264]. Taxotere® used to be the only FDA-
approved DCX formulation on the U.S. market. Generic DCX products that are currently 
in the U.S. include formulations launched by Hospira, Sagent, Accord, which are all 
DCX in Tween80/ethanol solutions. Docefrez® is a lyophilized DCX powder to be 
reconstituted with 3.54% ethanol in Tween 80 before injection. DCX has low water 
solubility (~5 µg/ml) [265], and Tween 80 and ethanol are used in the current DCX 
formulations to solubilize DCX.  
            The main aim in the present study was to rationally design a Tween 80-free 
formulation of DCX that also improves the antitumor activity of DCX. Based on a study 
by Huynh et al., where the authors reported that DCX solubility in low melting point 
triglycerides, such as tributyrin, tricaproin, and tricaprylin, is 10,000-20,000 times more 
than in water [259], we postulated that triglycerides-based SLN formulations may exhibit 
attractive drug-excipient interaction, facilitating incorporation of DCX in the 
nanoparticles. Four different medium- and long-chain saturated triglycerides that are 
solid at body temperature were employed in this study; namely, trilaurin (m.p. 46°C), 
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trimyristin (m.p. 57°C), tripalmitin, (m.p. 66°C), and tristearin (m.p. 69°C) with fatty 
acid-chain lengths of 12 (C12:0), 14 (C14:0), 16 (C16:0), and 18 (C18:0) carbon atoms, 
respectively. It was reported that triglycerides with melting points lower than room 
temperature form nano-droplets that are prone to coalescence during preparation or 
storage [252;253]. The use of high melting point triglycerides may significantly decrease 
the mobility of the drug molecules within the lipid core and thus reduce immature drug 
leakage [253;257].  
            Therefore, tricaprylin (C8:0, m.p. 9°C), tricaprin (C10:0, m.p. 31°C), and trolein 
(C18:1, m.p. 5°C) were excluded. The trimyristin-based SLN formulation was chosen 
from the four tested formulations because the rate at which the DCX was released from 
them was the slowest (Figure 2.1), and the SLNs were also more stable (Figure 2.2). In a 
mouse model with pre-established TC-1 mouse tumors, the DCX-SLNs were 
significantly more effective than DCX in T80/E in inhibiting the tumor growth (Figure 
2.6), likely because the DCX-SLNs significantly increased the accumulation of DCX in 
tumor tissues (Figure 2.7A). Circulating nano-carriers usually take advantage of the leaky 
vasculature and/or poor lymphatic drainage in tumor tissues to accumulate in tumors 
[91;266]. Since DCX accumulation in tumor was only significantly higher at 12 h, but not 
at 2 h, following the administration of SLNs, as compared to the DCX in T80/E, it is 
likely that the enhanced retention of the DCX-SLNs in tumors due to poor lymphatic 
drainage was responsible for the improved accumulation [91;94]. Small molecules may 
also exhibit enhanced permeation to tumors as well due to the leaky neovasculature in the 
tumor tissues, however, they can easily diffuse out of tumors as well, while 
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macromolecules and nano-carriers are entrapped and consequently accumulate 
[83;87;89]. 
            DCX not only induces apoptosis due to microtubule assembly stabilization, but 
also is antiangiogenic [238;267]. Inhibition of the formation of new blood vessels that 
provide rapidly growing tumors with increasing nutritional demand is expected to stunt 
the tumor growth [86;88;109]. Furthermore, the hastily-formed tumor-associated 
vasculature is characterized with various fenestration and imperfections, and almost 
lacking any intact lymphatic drainage [87;91;94;268]. Nanoparticles are known to take 
advantage of this leaky tumor vasculature to extravasate into the tumor 
microenvironment, where they can accumulate [266]. Several groups have reported lipid 
nanoparticle-based DCX formulations before [38;210;253;269-271]. The most widely 
used lipid excipients are soy lecithin, glycerides, or a mixture of the two. For example, 
Liu et al. formulated DCX into a nano-structured lipid carrier composed of soy lecithin, 
glyceryl monostearate, and fatty acids [271], but the DCX in nano-structured lipid carrier 
was only slightly more effective than a DCX in a T80/E formulation (Duopafei®) against 
B16 tumors in mice [271]. Xu et al. designed a trimyristin-based SLN formulation for 
DCX to treat hepatocellular carcinoma [38]. To improve their liver uptake, the SLNs 
were not PEGylated. Instead, their surface was galactosylated to target asialoglycoprotein 
receptors overexpressed on the surface of hepatoma cell lines [38].  
We previously reported the formulation of DCX-loaded lecithin-based PEGylated 
SLNs [210]. The resultant SLNs showed an improved in vitro cytotoxic activity, in 
addition to improved tumor accumulation in a mouse model. However, the capacity of 
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this formulation in incorporating DCX was limited, which may be attributed to the 
limited affinity between DCX and the excipients [210]. In the present study, in order to 
rationally select the most suitable excipient, four DCX-SLN formulations were prepared 
using four different high melting point triglycerides.  
As discussed previously, a successful formulation for taxane is the one that 
exhibits (a) long plasma circulation time, (b) long drug retention within the delivery 
carrier, which requires high drug-excipient affinity and slow release, (c) high tumor 
accumulation, and (d) favorable biodistribution profile, as less drug goes to healthy 
tissues [44]. Drug release behavior from the DCX-SLNs and short-term stability were the 
criteria for triglyceride selection in this study. In this regard, the absence of a burst 
release of DCX from the DCX-SLNs in the first 2 h and a subsequent slower release rate 
predict a limited drug leakage from the nanoparticles in the blood circulation before 
reaching tumors [272]. The release of DCX from the tristearin-based and trilaurin-based 
DCX-SLNs was relatively faster (Figure 2.1), and the tripalmitin- and trilaurin-based 
DCX-SLNs showed instability, as the zeta potential changed significantly following a 
short-term storage (Figure 2.2). Change in zeta potential has been used as an indicator of 
nanoparticle instability [273;274]. Several reports indicated that trilaurin does not exist in 
the solid state within the SLNs, but rather as a ‘supercooled-liquid state’ that resembles 
O/W emulsions, even at 4°C, which was not the case with triglycerides having higher 
melting points [273;275;276]. The relatively faster release of DCX from the trilaurin-
based SLNs may also arise as a result of the same phenomenon. As to the SLNs prepared 
with tripalmitin, the ‘super-cooled liquid state’ phenomenon was not reported, therefore, 
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the reasons to which this sign of instability may be attributed need to be investigated. On 
the other hand, the absence of a burst release of DCX from the DCX-SLNs prepared with 
trimyristin may infer a strong DCX-trimyristin interaction. It was reported that the 
solubility of DCX in tributyrin (4 C-chain) is about 108 mg/ml, and it gets lower with 
higher chain length, reaching about 56 mg/ml with tricaprylin (8 C-chain) [259]. Based 
on this, and since DSC and XRD data (Figure 2.4) implied that there is a strong 
interaction between DCX and the excipients, it is speculated that DCX exists in the SLNs 
either in a non-crystalline state and/or a dissolved state, within the lipid matrix. Existence 
of DCX in the amorphous state within lipid-based matrices was also reported previously 
[40]. The disappearance of the characteristic DCX-related peaks in DSC and XRD was 
previously shown to be related to the loss of DCX crystallinity [40;277]. In fact, we also 
found that the characteristic melting peak of DCX at 167°C completely disappeared upon 
analyzing the thermal behavior of DCX-trimyristin mixtures at DCX to trimyristin ratios 
of 1:5, 1:2, and 1:1 using DSC (data not shown), suggesting the prevalence of a strong 
interaction between the DCX and trimyristin. The relatively slower release of DCX from 
trimyristin-based DCX-SLNs may also be attributed to the strong DCX-lipid interaction 
as well.  
            Finally, potential toxicity issues were also considered during excipient selection. 
Long chain triglycerides in soybean oil and egg yolk phospholipids are commonly used 
in intravenous fat emulsions as components of parenteral nutrition for patients who are 
not able to receive nutrition via oral diets (e.g., Intralipid®, B Braun Medical Inc., 
Bethlehem, PA). Triglycerides are metabolized in the blood by lipases into corresponding 
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fatty acids, which are cleared from the blood within about 30 min [278]. 
Phosphatidylcholine and PEGylated phosphoethanolamine are used in products that are 
approved for intravenous infusion in humans (e.g., Doxil®). Therefore, we expect that our 
new DCX-SLN formulations will likely have a favorable safety profile. In fact, the body 
weights of the tumor-bearing mice that were treated with the DCX-SLNs did not 
significantly change by the end of the efficacy study (Figure 2.6B). In addition, the 
concentrations of DCX in vital organs such as liver, spleen, kidneys, lungs, and heart of 
mice that were injected with the DCX-SLNs were significantly lower than in mice that 
were injected with the DCX in T80/E formulation (Figure. 7), indicating that our DCX-
SLNs may be less damaging to those vital organs than Taxotere®.  
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2.5 Conclusion 
In the present study, by taking advantage of the high solubility of DCX in triglycerides, 
we successfully prepared several DCX-incorporated SLNs using various medium- and 
long-chain triglycerides. The DCX-SLN composition prepared with trimyristin was 
selected for further evaluation because the resultant DCX-SLNs were stable in a short-
term stability study, and the rate at which the DCX was released from them was the 
slowest. The DCX-SLNs showed a stronger antitumor activity than DCX solubilized in a 
Tween 80/ethanol mixture in cell culture and, more importantly, in a mouse model with 
pre-established tumors, likely because the DCX-SLNs significantly increased the 
accumulation of the DCX in tumor tissues. The decreased accumulation of DCX in vital 
organs after i.v. injection of DCX-SLNs, relative to after injection of DCX solubilized in 
a Tween80/ethanol mixture, suggests that the DCX-SLNs may have a favorable safety 
profile. 
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Chapter 3 
Synthesis, characterizations, and in vitro and in vivo evaluations of 4-(N)-
docosahexaenoyl 2´, 2´-difluorodeoxycytidine with potent and broad spectrum 
antitumor activity 
 
3.1 Introduction 
Docosahexaenoic acid (DHA, omega-3, 22:6, n-3) is a polyunsaturated fatty acids 
(PUFA) that has been extensively investigated for its potential antitumor activity, either 
as a single agent or in combination with other cancer chemotherapeutic agents [279-283]. 
It was shown that omega-3 PUFAs  induce apoptosis in various cancer cells [284;285], 
inhibit cancer cell invasiveness [286], and inhibit metastasis and angiogenesis in tumor 
tissues [287-289]. The mechanism underlying the antitumor efficacy of omega-3 PUFAs 
remains unclear, but it is thought to be related to its potent anti-oxidant activity [284]. In 
order to better take advantage of the antitumor activity of DHA, it was previously 
conjugated with some commonly used anti-cancer chemotherapeutic agents, such as 
paclitaxel, doxorubicin, and camptothecin [290-292]. For example, Bradley et al. showed 
that conjugation of DHA to paclitaxel significantly modified the pharmacokinetics and 
biodistribution of paclitaxel, prompting the testing of the DHA-paclitaxel conjugate (i.e., 
Taxoprexin) in clinical trials [293;294], although the DHA–paclitaxel conjugate was not 
more cytotoxic than paclitaxel alone against many tumor cells in culture [292;295;296]. 
Gemcitabine HCl (2`, 2`-difluorodeoxycytidine HCl, dFdC) is a fluorinated 
deoxycytidine analogue. It is the standard treatment of locally advanced and metastatic 
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pancreatic cancer [297;298] and is also used in combination therapy to treat various other 
solid tumors including breast, bladder, lung, and ovarian cancers [297;299;300]. In 
pancreatic cancer, the drug is administered at a 1000 mg/m2 intravenous infusion over 30 
min once/week for 7 weeks followed by a one week’s rest, then once weekly for up to 3 
weeks in a 28 days’ cycle, and while this dosage regimen is changed in case of non small 
cell lung cancer, ovarian cancer, and breast cancer, the recommended short infusion time 
(< 70 min) keeps the infusion time-dependant plasma half life relatively short [301-303]. 
Extensive deamination at the 4-amino site, which takes place both intracellularly and 
extracellularly by the action cytidine deaminase, is responsible for the loss of about 90% 
of the drug, and the deaminated metabolite difluorodeoxyuridine (dFdU) is almost 
inactive [39;179;193;297;304]. More than 99% of administered dFdC is excreted in the 
urine, with unchanged dFdC comprising only 5%, and the rest is the long-circulating 
dFdU, which has a terminal phase half life of about 22 h [297;305]. Over the years, there 
have been reports showing that chemical modifications of this fluorinated deoxycytidine 
analogue may potentially improve its efficacy and/or safety profile. For example, it was 
shown that conjugation of a fatty acid, such as stearic acid or lauric acid, to dFdC at the 
4-NH2 group decreases the sensitivity of the latter to deaminase, modifies its 
pharmacokinetics, and in some cases, improves its in vivo antitumor activity 
[39;114;208;219;301;302;306-315] 
In the present study, we report the synthesis, characterization, and in vitro and in 
vivo evaluations of 4-(N)-docosahexaenoyl 2´, 2´-difluorodeoxycytidine (DHA-dFdC) 
conjugate. DHA-dFdC showed broad spectrum and potent antitumor activity in various 
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human cancer cell lines. Because DHA-dFdC showed an unexpectedly longer residence 
time in mouse pancreas, compared to dFdC, and since pancreatic cancer is one of the 
most aggressive, and in most cases fatal, types of cancer, with a mortality rate almost 
equal to incidence rate [316;317], the antitumor activity of the DHA-dFdC was primarily 
evaluated in mouse models of pancreatic cancer. 
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3.2 Materials and Methods 
 
3.2.1 Materials 
Gemcitabine HCl (dFdC) was from Biotang, Inc. (Lexington, MA). Cis-
4,7,10,13,16,19-docosahexaenoic acid (DHA) and trifluoroacetic acid (TFA) were from 
Acros Organics (Morris Plains, NJ). Di-tert-butyl-dicarbonate, 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCl), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), HPLC grade methanol, 
and Tween 80 were from Sigma-Aldrich (St Louis, MO). Hydroxy-7-azabenzotriazole 
(HOAt) was from CreoSalus, Inc. (Louisville, KY). Isopropyl myristate (IPM) was from 
TCI America (Montgomeryville, PA). Anhydrous sodium sulfate, ammonium chloride, 
mono- and di-basic sodium phosphates, ethyl acetate, HPLC-grade acetonitrile, 
dichloromethane (DCM), acetone, hexane, and octanol were from Thermo Fisher 
(Waltham, MA). BD MatrigelTM Basement Membrane Matrix was from BD Biosciences 
(San Jose, CA). D-Luciferin K+ salt bioluminescent substrate was from Perkin Elmer 
(Waltham, MA). Guava Nexin reagent for flow cytometry was from EMD Millipore 
(Billerica, MA). Lactate dehydrogenase (LDH) cytotoxicity detection kit was from 
Takara (Clonetech Laboratories, Mountain View, CA). Dulbecco’s modified Eagle 
medium (DMEM), Roswell Park Memorial Institute (RPMI 1640) medium, fetal bovine 
serum (FBS), penicillin, streptomycin, horse serum, and Dulbecco’s phosphate buffer 
saline (DPBS) were all from Invitrogen-Life Technologies (Carlsbad, CA). All other 
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chemicals, reagents, and solvents were of analytical grade and used as received without 
further purification.   
 
3.2.2 Cell lines  
Panc-02 (mouse pancreatic cell line), BxPC-3 (human pancreatic cancer cell line), 
MIA PaCa-2 (human pancreatic cancer cell line), and TC-1 (mouse lung cancer cell line) 
were from the American Type Culture Collection (ATCC, Manassas, VA). Panc-1-Luc 
human pancreatic cell line was generously provided by Dr. Dawn E. Quelle at the 
University of Iowa [318]. TC-1 and Panc-02 cells were grown in RPMI 1640 medium. 
BxPC-3, MIA PaCa-2, and Panc-1-Luc cells were grown in DMEM. All media were 
supplemented with 10% FBS, 100 U/ml of penicillin, and 100 g/ml of streptomycin, and 
the DMEM for MIA PaCa-2 cells was supplemented additionally with 2.5% horse serum. 
  
3.2.3 Synthesis of 4-N-docosahexaenoyl 2´, 2´-difluorodeoxycytidine (DHA-dFdC) 
(3)  
  DHA-dFdC  was synthesized following a previously reported conjugation 
scheme with slight modifications [39;193;208] (Scheme 3.1). dFdC (1) (200 mg, 0.67 
mmol) in 13.3 ml of 1 N potassium hydroxide was cooled to 4° C. To this solution, di-
tert-butyl dicarbonate (Boc2O, 1.483 g, 6.8 mmol) in about 13.3 ml of anhydrous dioxane 
was added over 10 min under argon atmosphere as previously reported [319]. The 
reaction mixture was stirred at room temperature (~22° C) for 1 h and extracted with 
ethyl acetate (EtOAc). The organic layer was washed with brine, dried over anhydrous 
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sodium sulfate (Na2SO4) and filtered. Solvent was removed under reduced pressure. The 
residue was added to Boc2O (1.483 g, 6.8 mmol) in 13.3 ml of anhydrous dioxane and 
13.3 ml of 1 M KOH at room temperature. The reaction was monitored by thin-layer 
chromatography (TLC). After 1 h, the reaction mixture was extracted to EtOAc. The 
organic layer was washed with brine, dried over anhydrous Na2SO4, and filtered. Solvent 
was then removed, and the crude product was purified by column chromatography (DCM 
to acetone, 1:1, v/v). The desired product fractions were pooled and dried to yield 219 mg 
(71 %) of 3`,5`-O-bis(tert-butoxycarbonyl) dFdC (2). 1H NMR (500 MHz, acetone-d6) δ 
7.60 (1 H, d, J = 7.6 Hz, 6-CH), 6.34 (1 H, brs, 1`-CH), 5.97 (1 H, d, J = 7.6 Hz, 5-CH), 
5.29 (1 H, brs, 3`-CH), 4.53-4.39 (3 H, m, 4`-CH, 5`A-CH, 5`B-CH), 2.82 (2 H, s, NH2) 
1.50, 1.47 (18 H, two s, (CH3)3C). A solution of 3`,5`-O-bis(tert-butoxycarbonyl) dFdC 
(150 mg, 324 µmol), DHA (123 mg, 373.9 µmol) and HOAt (75 mg, 551.1 µmol) in 
anhydrous DCM was pre-cooled to 4oC, and EDCI (93.75 mg, 604.1 µmol) was added. 
The mixture was de-gassed by vacuum sonication and then stirred at room temperature 
under argon for about 40 h. Water (5 ml) was added to the reaction mixture and extracted 
three times with a mixture of EtOAc and hexane (2:1, v/v). The combined organic phase 
was washed with saturated ammonium chloride (NH4Cl) and brine and then dried over 
anhydrous Na2SO4. The solvent was evaporated, and the residue was purified by column 
chromatography (EtOAc to Hexane, 3:7, v/v). The conjugated amide was isolated and 
quantified (~165 mg). 1H NMR was as follows: (300 MHz, acetone-d6) δ 9.18 (1 H, s, 
NHCO), 7.83 (1 H, d, J = 7.8 Hz, 6-CH), 7.49 (1 H, d, J = 7.8 Hz, 5-CH), 6.47-6.42 (1 H, 
m, 1′-CH), 5.42-5.30 (12 H, m, CH2), 5.30-5.05 (1 H, m, 3′-CH), 4.50–4.34 (3 H, m, 4′-
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CH and 5′-CH), 2.90-2.79 (10 H, m, CH2), 2.60-2.40 (4 H, m, CH2), 2.07 (2 H, p, J = 7.5 
Hz, CH2), 1.53-1.46 (18H, m, (CH3)3C), 0.97 (3 H, t, J = 7.4 Hz, terminal CH3). To a 
stirred solution of the conjugated amide (37 mg, 47.8 nmol) in 3 ml of DCM, about 0.2 
ml of TFA was added. This solution was stirred at room temperature for 4 h, and excess 
TFA was removed under reduced pressure. The concentrated sample was co-distilled 
with DCM for 3 times. The crude sample was chromatographed on silica gel (DCM to 
ethanol, 94:6, v/v) [193;301]. The desired fractions were pooled, and the solvent was 
evaporated to yield 4-(N)-DHA-dFdC (DHA-dFdC, 3, ~80 mg, ~36% of original 
combined weights of dFdC and DHA). 1H NMR (300 MHz, THF-d4) was as follows: δ 
10.13 (1H, s, NHCO), 8.17 (1H, d, J = 7.5 Hz, 6-CH), 7.37 (1H, d, J = 7.5 Hz, 5-CH), 
6.25 (1H, t, J = 7.4 Hz, 1′-CH), 5.51–5.27 (12H, m, CH), 4.40-4.20 (1H, m, 3′-CH), 3.95–
3.70 (3H, m, 4′-CH and 5′-CH), 2.95-2.82 (10H, m, CH2), 2.50-2.41 (4H, m, CH2), 2.08 
(2H, p, J = 7.2 Hz, CH2), 0.96 (3H, t, J = 7.7 Hz, terminal CH3) (see Figure 3.1A for 1H 
NMR spectrum). ESI-HRMS [M+Na] + m/z calculated for C31H41F2N3NaO5 is: 
596.29065, found: 596.29068. 
The purity of the synthesized compound was confirmed by LC/MS following 
gradient elution (Figure 3.1B and C). The LC/MS system used was an Agilent 
Technologies 6530 Accurate Mass Quadruple TOF LC/MS using a RP C18 column 
(Agilent Zorbax, 50 x 2.1 mm, 5 µm) at 40ºC. The mobile phase consisted of solvent A 
(water with 0.1% formic acid) and solvent B (acetonitrile with 0.1 % formic acid). 
Mobile phase composition was changed from 95% solvent A to 100% solvent B over 5 
min, ran for 2 more minutes, and finally changed back to 95% solvent A over 4 more 
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minutes. The flow rate was 0.7 ml/min. The target compound was detected at 4.85 min, 
and the compound was observed as [M+H] + m/z at 574.3, [M+Na] + m/z at 596.3, 
[2M+H] + m/z at 1147.6, and [2M+Na] + m/z at 1169.6 (Figure 3.1C).         
4-(N)-arachidonyl dFdC (ARA-dFdC) was synthesized similarly, except that the 
DHA was replaced with arachidonic acid (ARA), an omega-6 polyunsaturated fatty acid 
(Scheme 3.1). The structure of the resultant ARA-dFdC was confirmed using 1H NMR 
and Mass Spectroscopy. 
 
3.2.4 Determination of the solubility and partition coefficient of DHA-dFdC 
The aqueous solubility of DHA-dFdC was determined following an indirect 
method according to Beall et al. with minimal modifications [320]. Briefly, excess 
amount of DHA-dFdC was added to 100 µl of IPM in a crimp-sealed amber glass vials 
under nitrogen and was stirred vigorously at room temperature for 24 h, protected from 
light. After the stirring was stopped, the mixture was left to stand for an additional 24 h 
for equilibration. The content of the vial was centrifuged (14,000 rpm, 10 min) and the 
supernatant was transferred into a different tube. Aliquots of the saturated IPM solution 
were used to measure the DHA-dFdC concentration before partitioning (A1) using HPLC 
(after proper dilution with methanol). The HPLC method will be discussed in details 
later. Then, water was added to the IPM saturated solution in a volume ratio of 10:1. The 
two phases were mixed by vortexing for 5 min, left to stand for 15 min, and then 
centrifuged (14,000 rpm, 15 min) to collect the IPM layer. DHA-dFdC concentration in 
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the IPM layer (A2) was again measured using HPLC after partitioning. The following 
equation was used to calculate the partition coefficient (KIPM/water) [320]: 
 
KIPM/water = [A1 / (A1 – A2)] x [Vwater / VIPM]     (equation 3) 
 
Where Vwater is the volume of the water phase and VIPM is the volume of IPM, and the 
value of Vwater / VIPM was 10.  
 
The aqueous solubility (Sw) of DHA-dFdC was determined using the following 
equation [320]: 
Sw = SIPM / KIPM/water         (equation 4) 
 
Where SIPM is the solubility of DHA-dFdC in IPM, and DHA-dFdC was found to be 
stable in IPM under test conditions for at least 48 h. 
 
The octanol-water partition coefficient of DHA-dFdC was determined using a 
previously reported method with minor modifications [321]. Briefly, octanol and PBS 
(7.4, 0.01 M) were mutually saturated for 24 h. DHA-dFdC was dissolved in octanol (0.4 
mg/ml, PBS-saturated) and 10 µl of the solution were withdrawn and diluted with 
methanol to measure DHA-dFdC concentration using HPLC (C1). PBS was added to 
octanol at a volume ratio (VPBS / Voct) of 20:1 into a sealed vial under nitrogen, and the 
mixture was agitated vigorously at room temperature using a horizontal orbital shaker at 
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250 rpm (Max Q 2000, Thermo Scientific, Waltham, MA) while protected from light. 
After 5 h, the mixture was centrifuged (14,000 rpm, 15 min) and the concentration of 
DHA-dFdC in the octanol layer was determined using HPLC (C2). Partition coefficient 
(Koct/water) was calculated using the following equation: 
 
Koct/water = [C1 / (C1 – C2)] x [VPBS / Voct]                 (equation 5) 
 
DHA-dFdC was found to be stable in octanol under the test conditions for at least 
18 h. 
 
3.2.5 Chemical stability of DHA-dFdC in an aqueous solution  
DHA-dFdC is freely soluble in ethanol and in Tween 80. It was solubilized into a 
formulation that contains Tween 80, ethanol, and water at a volume ratio of 1:0.52:8.48 
to evaluate its in vivo activity. The stability of DHA-dFdC in this formulation was 
evaluated in crimp-sealed amber glass vials under nitrogen atmosphere. Briefly, 150 µl of 
the DHA-dFdC aqueous solution at a concentration of about 7 mg/ml were added to the 
amber glass vials under nitrogen atmosphere, and the vials were crimp-sealed with 
aluminum seals over rubber lids. At predetermined time intervals, 10 µl of the solution 
were diluted with 90 µl of methanol and mixed, and the concentration was measured 
using HPLC. Stability tests were carried out at room temperature (~22oC) or 4ºC in 
triplicates. Vitamin E was added in the formulation to a final concentration of 0.01% or 
0.04 % (v/v) to evaluate the effect of vitamin E on the chemical stability of DHA-dFdC.   
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To study the effect of temperature on the chemical stability of DHA-dFdC, the 
DHA-dFdC formulation in crimp-sealed vials under nitrogen was stored in room 
temperature, 37ºC, or 60ºC, protected from light. Sampling and analyses were carried out 
at pre-determined time points as described above. The first order degradation reaction 
equation was used to calculate the values of the reaction rate (k) at different temperatures. 
Arrhenius plot was constructed by plotting the log k values vs. 1/T to calculate the 
activation energy (Ea, in kcal/mol). 
 
3.2.6 Physicochemical characterizations of DHA-dFdC 
The UV-Vis absorbance of DHA-dFdC, DHA, dFdC, and the physical mixture of 
dFdC and DHA, all dissolved in methanol, were evaluated using a BioTek Synery HT 
Multi-Mode Microplate Reader (Winooski, VT) using the scanning mode. Modulated 
differential scanning calorimetry (DSC) was used to evaluate the thermal properties of 
DHA-dFdC. Samples (2-4 mg) were placed in sealed pans, and the DSC analysis was 
carried out using DSC Q200 (TA instruments, New Castle, DE) at a ramp rate of 5ºC/min 
under nitrogen flow. X-ray diffraction (XRD) analyses of DHA-dFdC, dFdC, DHA, and 
the physical mixture of dFdC and DHA (1:1, m/m) was carried out in the X-ray facility in 
the Department of Chemistry at the University of Texas at Austin using a Rigaku Spider 
single crystal X-ray diffractometer (Rigaku, Tokyo, Japan).    
 
3.2.7 Evaluation of the anti-proliferative, cytotoxic, and pro-apoptotic activity of 
DHA-dFdC in tumor cells in culture 
 92 
The anti-proliferative activity and cytotoxicity DHA-dFdC were tested using the 
NCI-60 DTP Human Tumor Cell Line Screen service 
(http://dtp.nci.nih.gov/branches/btb/ivclsp.html) using one-concentration and then five-
concentrations. The NCI-60 cell lines do not include any pancreatic cancer cell lines. 
Therefore, DHA-dFdC antitumor activity was also evaluated in mouse (Panc-02) and 
human (Panc-1-Luc, MIA PaCa-2, and BxPC-3) pancreatic cell lines. TC-1 is a mouse 
lung cancer cell line that grows aggressively in mouse model [39], and thus the 
cytotoxicity of DHA-dFdC was also evaluated in TC-1 cells. For TC-1, Panc-02, BxPC-3 
and Panc-1-Luc cells, cells (1,500/well for Panc-02, BxPC-3, and Panc-1-Luc, and 
3,000/well for TC-1) were seeded in 96-well plates and incubated at 37º C and 5% CO2 
overnight. The cells were then treated with various concentrations of DHA-dFdC, dFdC, 
DHA, or physical mixture of dFdC and DHA (1:1 molar ratio, DHA + dFdC) for 24 h for 
Panc-1-Luc and TC-1, 48 h for Panc-02, and 72 h for BxPC-3. Cell survival was 
determined using an MTT assay as previously described [322]. dFdC was dissolved in 
cell culture media, whereas DHA-dFdC, DHA, and DHA in the mixture were dissolved 
in dimethylsulfoxide (DMSO). In a separate experiment, Panc-02 cells were also treated 
for 4 h with higher concentrations of DHA-dFdC (i.e., 10-100 µM) or molar equivalent 
concentrations of dFdC, DHA, or dFdC + DHA 1:1 m/m mixture and cytotoxicity was 
measured using MTT assay. The cytotoxic activity of DHA-dFdC in Panc-02 cells was 
also evaluated using an LDH assay kit (Takara Clonetech, Mountain view, CA). Panc-02 
cells (1500 cells/well) were seeded in 96-well plates and incubated at 37ºC and 5% CO2 
for 24 h, followed by treatment with DHA-dFdC or dFdC as mentioned above for 48 h. 
 93 
LDH activity in the cell culture medium was determined following the manufacturer’s 
instruction. Finally, the anti-proliferative activity of the ARA-dFdC was also evaluated in 
MIA-PaCa-2 and BxPC-3 cells using MTT assay (1000 cells/well and then treated with 
various concentrations of ARA-dFdC for 72 h). The values of IC50 were calculated using 
either GraphPad Prism (GraphPad software, Inc., La Jolla, CA) or Microsoft Excel.  
Apoptosis analysis was carried out as previously reported [209], Briefly, 100,000 
Panc-02 cells were incubated in 24-well plates for 24 h at 37ºC and 5% CO2 and then co-
incubated with various concentrations of DHA-dFdC for 48 h. The cells were then 
harvested and stained with 0.1 ml of Guava Nexin reagent (Millipore Corporation, 
Billerica, MA) for 20 min at room temperature, protected from light. The stained cells 
were analyzed using a Millipore Guava easyCyte 8HT Flow Cytometry System. Control 
cells were left untreated. 
  
3.2.8 Cellular uptake of DHA-dFdC 
The uptake of DHA-dFdC by Panc-02 cells was evaluated. Briefly, 250,000 cells 
were seeded in 12-well plates and incubated overnight, followed by the addition of DHA-
dFdC (or dFdC as a control) to a final concentration of 10 µM. Four hours later, the 
medium was removed, and cells were lysed using a 500 µl of 1:1 mixture of 2% sodium 
dodecyl sulfate (SDS) and 1% Triton X for 15 min at room temperature. The cell lysate 
was centrifuged (14,000 rpm, 10 min), supernatant collected, and 25 µl of which was 
used for protein assay using Pierce BCA protein assay kit (Life technologies, Carlsbad, 
CA). For cells that were incubated with dFdC, prior to the centrifugation of the cell 
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lysate, tetrahydrouridine (THU, 40 g) were added into the cell lysate to inhibit de-
amination, and deoxyuridine (dU, 0.4 µg) was added as an internal standard. DHA-dFdC 
was extracted from the cell lysate using ethyl acetate, which was evaporated under 
nitrogen, and the residue was re-dissolved in 100 µl of methanol and analyzed by HPLC. 
To extract dFdC, the cell lysate was mixed with acetonitrile for protein precipitation, 
followed by centrifugation and collection of the supernatant, which was evaporated under 
air stream at 45ºC. The residue was re-dissolved in 200 µl of water and analyzed using 
HPLC. Standard curves of DHA-dFdC and dFdC in cell lysates were constructed. 
 
3.2.9 Pharmacokinetics and biodistribution of DHA-dFdC 
Animal protocols were approved by the Institutional Animal Care and Use 
Committee at the University of Texas at Austin. Healthy female C57BL/6 mice (6-8 
weeks, Charles River Laboratories, Wilmington, MA) were injected intravenously (i.v.) 
with DHA-dFdC solution in Tween 80/ethanol/water (with 5% mannitol) at a dose of 75 
mg/kg. At various time points (5, 15, 30, 60, 120, and 180 min), 3 mice were euthanized 
at each time point to collect blood by cardiac puncture. DHA-dFdC was extracted from 
plasma using ethyl acetate and analyzed using HPLC. Data were analyzed using the 
Pharsight WinNonlin software (Sunnyvale, CA).  
Biodistribution study was carried out in healthy female BALB/c mice (14-16 
weeks old, Charles River). DHA-dFdC was i.v. injected at a dose of 75 mg/kg, and 
organs were collected after 1 h and weighed. In addition, the pancreatic content of DHA-
dFdC was measured in the pancreas of female BALB/c mice (14-16 weeks, Charles 
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River) after i.v. injection (75 mg/kg), followed by euthanization of mice and collection of 
pancreas at predetermined time points (5, 25, 60, 90, 330, and 720 min). DHA-dFdC was 
extracted by ethyl acetate and analyzed by HPLC. As a control, the content of dFdC in 
mouse pancreas at various time points after i.v. injection of dFdC (75 mg/kg in 5% 
mannitol solution) was determined. Before extraction of dFdC, THU (4 µg) was added as 
deoxycytidine deaminase inhibitor, and dU (40 µg) was added as an internal standard. 
dFdC concentration was determined using HPLC.  
Biodistribution of DHA-dFdC was also confirmed in C57BL/6 mice with pre-
established subcutaneous TC-1 tumors. When tumor diameters reached 7-8 mm, mice 
were injected via the tail vein with a DHA-dFdC solution (75 mg/kg). Ninety minutes 
later, mice were euthanized to collect major organs (e.g., liver, kidneys, spleen, lung, 
heart, and pancreas), and the contents of DHA-dFdC in each organs were determined 
using HPLC after extraction. Similar experiment was repeated in mammary M-wnt 
tumor-bearing C57BL/6 mice (7-8 mm) following injection of 37.5 mg/kg of DHA-dFdC 
by i.v. injection.  
 
3.2.10 HPLC 
HPLC analysis of DHA-dFdC was performed using an Agilent Infinity 1260 
(Agilent Corp., Santa Clara, CA) with a RP-C18 column (Zorbax Eclipse, 5µm, 4.5 mm x 
150 mm, Santa Clara, CA).The mobile phase was methanol and water (90:10, v/v). The 
flow rate was 1.0 ml/min, and the detection wavelength and injection volume were 248 
nm and 5 µl, respectively. When cell lysate, mouse plasma or tissue samples were used, 
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the mobile phase was methanol and 1% (v/v) acetic acid in water (85:15, v/v) with a flow 
rate of 1.2 ml/min and injection volume of 20 µl. When pancreas samples were used, the 
wave length of detection of DHA-dFdC was set to 300 nm.  
The concentration of dFdC was determined using a previously reported method 
with modifications [323]. Briefly, an Agilent 1260 Infinity HPLC Station equipped with a 
RP-C18 column (Zorbax Eclipse, 5µm, 3 mm x 150 mm, Santa Clara, CA) at a controlled 
temperature of 20°C, an Agilent quaternary pump and Agilent Diode array UV detector 
was used. The mobile phase was composed of solution A (phosphate buffer, pH adjusted 
to 3.0 using phosphoric acid) and solution B (acetonitrile). The column was equilibrated 
using solution A for at least 30 min at a flow rate of 0.6 ml/min, followed by another 30 
min at 1.2 ml/min. The gradient elution consisted of 100% solution A for 6 min, followed 
by a gradual change to 97% solution A and 3% solution B over 1 min. This composition 
was maintained for 2 min, and the composition was returned back to 100% solution A 
over 1 min. Between runs, the column was rinsed with methanol:water (90:10), 
methanol:water (50:50), and then solution A for 15 min each. The flow rate was 1.2 min. 
 
3.2.11 Evaluation of the antitumor activity of DHA-dFdC in animal models 
 
3.2.11.1 Transgenic mice with spontaneously developed pancreatic tumors. 
             Kras Ink4A+/- spontaneous pancreatic tumor-bearing female mice were bred in 
the Animal Research Center at the University of Texas at Austin as previously reported 
[324]. In order to early investigate whether DHA-dFdC is effective in a pancreatic cancer 
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model that resembles human pancreatic cancer which becomes more aggressive when 
combined with obesity, mice were transferred to a special diet (D1249, 60% kcal fat, 
Research Diets, Inc, New Brunswick, NJ) at the age of 16 weeks ad libitum. Mouse body 
weight was monitored twice a week. Mice were then either treated with DHA-dFdC (50 
mg/kg, i.p., up to twice weekly, total of 29 doses, n = 5) or left untreated (n = 6) and their 
health and survival were monitored. In another experiment, following their transfer to a 
similar high fat diet at 10-12 weeks of age, mice were randomized into 2 groups (n = 6) at 
the age of 19-20 weeks and were treated with DHA-dFdC group (65 mg/kg, i.p., twice a 
week) or left untreated until week 30. They were then euthanized and their pancreas were 
collected, fixed in formalin, and embedded in paraffin blocks for histological evaluation.  
 
3.2.11.2 Mice with subcutaneous Panc-1-Luc tumors.  
            Male athymic nude mice (6-8 weeks, Charles River) were subcutaneously injected 
with Panc-1-Luc cells (5 x 106 cells in DMEM:Matrigel, 1:1 v/v). Five days later, tumors 
reached about 130 mm3 (tumor volumes (V) were calculated based on the longest 
diameter (L1) and the shortest diameter (L2) of each tumor using the equation of V = ½ x 
L1 x L2 x L2). Mice were randomized into 5 groups (n = 5-6) and injected i.p. with  DHA-
dFdC (in Tween 80/ethanol/water at a ratio of 1:0.52:8.48 with isotonicity adjusted with 
5% w/v mannitol, 50 mg/kg or ~ 0.087 mole/kg, n = 6), dFdC (in aqueous 5% w/v 
mannitol solution, 26.1 mg/kg or ~ 0.087 mole/kg, n = 6), DHA (in Tween 80/ethanol-
based solution, 28.7 mg/kg or ~ 0.087 mole/kg, n = 5), or the physical mixture of dFdC 
(26.1 mg/kg) and DHA (28.7 mg/kg) in a Tween 80/ethanol-based solution (n = 6). As a 
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vehicle control, mice were also injected with the Tween 80/ethanol-based solution alone 
(n = 6). Treatments were repeated twice a week for up to 6 times, and tumor growth was 
monitored using digital calipers.  
 
3.2.11.3 Mice with orthotopic Panc-1-Luc tumors.   
            Panc-1-Luc cell suspension was prepared at a concentration of about 2 x 107 per 
ml in a 1:1 (v/v) mixture of DMEM and Matrigel. Tumor cells were then injected into the 
pancreas of male athymic nude mice (6-8 weeks, Charles River) following a surgical 
procedure [325;326]. Briefly, after mice were anesthetized using isoflurane, the skin and 
peritoneum were cut open about 1 cm in length using sterile surgical scalpels. The 
pancreas was pulled out, and about 50 µl of the cell suspension were injected slowly until 
a small bleb was formed. After the needle was withdrawn, a small cotton plug was 
applied for 10 s. The pancreas was returned back, the peritoneum was sutured with 
Monocryl® bioresorbable sutures (Ethicon, Somerville, NJ), and the skin was then closed 
using surgical clips. Mice were s.c. injected with buprenorphine (0.1 mg/kg) as a pain 
killer and were left to heal for one week. Tumor progress was monitored using an IVIS® 
Spectrum imaging system (Caliper, Hopkinton, MA). For IVIS imaging, each mouse was 
i.p. injected with a luciferin solution (15 mg/ml) at a dose of 0.15 mg/g body weight in 
sterile DPBS, anesthetized with isoflurane, and imaged 10 min after luciferin injection. 
Four weeks after tumor implantation, mice with tumors were randomized into 3 groups (n 
= 5-7) and i.p. injected with DHA-dFdC (50 mg/kg, ~0.087 mole/kg), dFdC (26.1 mg/ml, 
~0.087 mole/kg), or left untreated. DHA-dFdC was in a Tween 80/ethanol/water solution 
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with 5% (w/v) of mannitol, and dFdC was dissolved in sterile mannitol solution (5%, 
w/v). Treatments were repeated twice a week for a total of 7 times. Thirty days after the 
first treatment, mice were sacrificed and tumors were dissected from the pancreas, 
weighed, and fixed in formalin, dehydrated in 70% ethanol, and embedded in paraffin 
wax.  
       In both studies mentioned above, the doses were based on the average weight of 
mice in the same group on the day of injection, and were adjusted only if the weight of an 
individual mouse was above or below 10% of the average weight.  
 
3.2.11.4 Mice with subcutaneous TC-1 tumors.  
            The in vivo antitumor activity of DHA-dFdC was also evaluated and compared to 
that of dFdC in female C57BL/6 mice (6-8 weeks, Charles River) with subcutaneously 
implanted TC-1 mouse lung cancer cells. Briefly, 5 x 105 cells in RPMI were s.c. injected 
in the right flank of female C57BL/6 mice (Charles River, 6-8 weeks). Eight days later, 
mice were randomized into 3 groups (n = 5-6) and i.p. injected with DHA-dFdC solution 
(50 mg/kg, ~ 0.087 mole/kg), dFdC solution (26.1 mg/kg, ~0.087 mole/kg), or left 
untreated as a control. Treatments were repeated every 3-4 days for a total of 4 times. 
Tumor growth was monitored using a digital caliper. 
 
3.2.12 Immunohistochemistry 
 Tumor tissues were sectioned and stained in the Histology and Tissue Analysis 
Core at Dell Pediatric Research Institute at the University of Texas at Austin or in the 
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Department of Molecular Carcinogenesis at the University of Texas M.D. Anderson 
Cancer Center at Science Park (Smithville, Texas) with hematoxylin & eosin (H&E), 
antibodies against cleaved lamin-A (apoptosis marker), CD-31 (angiogenesis marker), or 
Ki-67 (proliferation marker). Slides were then scanned, and images were taken using the 
ScanScope XT (Aperio Technologies, Vista, CA). Pancreas tissues were examined to 
evaluate the progression of pancreatic cancer (i.e., pancreatic intraepithelial neoplasia-1, -
2, and -3 (PanIN-1, -2, and -3), and pancreatic ductal adenocarcinoma (PDAC)). 
 
3.2.13 Statistical analysis 
            Statistical analyses were completed by performing ANOVA followed by Fisher’s 
protected least significant difference procedure. Survival curve comparisons were 
constructed using Kaplan−Meier survival analysis (GraphPad Prism, La Jolla, CA). The 
survival curves were compared using the log rank test (Mantel-Cox test). A p value of 
≤0.05 (two-tail) was considered statistically significant. 
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3.3 Results 
 
3.3.1 Synthesis and characterization of DHA-dFdC and ARA-dFdC 
DHA was conjugated to Boc2O-protected dFdC at the 4-(N) position via an amide 
linkage (Scheme 3.1). NMR, mass spectrometry, and LC/MS data confirmed the structure 
and purity of the compound (Figure 3.1), which is more than 99.8%. The drug appeared 
as pale yellow dry waxy flakes. As a control, ARA-dFdC, an omega-6 polyunsaturated 
fatty acid-dFdC conjugate, was synthesized similarly (Scheme 3.1).    
 
3.3.2 Solubility and partition coefficient of DHA-dFdC 
            Beall et al. reported a method to measure the aqueous solubility of drug molecules 
that are unstable in water [320], which was used in the present study. In order to validate 
the method, the aqueous solubility of 4-(N)-stearoyl dFdC, another lipophilic dFdC 
conjugate [39], which is stable in water, was measured directly (i.e., direct method) or 
using the indirect method reported by Beall et al. [320]. The solubility of 4-(N)-stearoyl 
dFdC in water was found to be 1.38 ± 1.6 µg/ml when it was measured using the direct 
method, and 1.39 ± 0.1 µg/ml using the indirect method. Therefore, the indirect method 
was used to measure the solubility of DHA-dFdC in water, which was found to be 25.15 
± 11.2 µg/ml. The partition coefficient (octanol/PBS 7.4) of DHA-dFdC was also 
measured using an indirect method by determining its concentration in octanol, before 
and after partitioning. The logP value of DHA-dFdC was found to be 2.24 ± 0.25. 
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    Scheme 3.1. Synthesis of DHA-dFdC and ARA-dFdC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DHA-dFdC 
Molecular mass: 
573.3014 g/mol 
Formula: C31H41F2N3O5 
ARA-dFdC 
Molecular mass: 
549.3014 g/mol 
Formula: C29H41F2N3O5 
DHA 
ARA 
DFdC 
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Figure 3.1. Characterization and confirmation of the chemical formula and 
structure of DHA-dFdC using NMR and mass spectrometry. (A) H1 NMR spectrum 
of DHA-dFdC (300 MHz, THF-d4). (B) Mass spectra of DHA-dFdC, the compound was 
observed as [M+H] + m/z at 574.3, [M+Na] + m/z at 596.3, [2M+H] + m/z at 1147.6, and 
[2M+Na] + m/z at 1169.6. (C) LC/MS chromatogram of DHA-dFdC.  
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3.3.3 Chemical stability of DHA-dFdC  
DHA-dFdC solubilized in a Tween 80/ethanol/water formulation was found to 
degrade considerably at room temperature (~22oC) (Figure 3.2A). The degradation was 
significantly slower at 4ºC and was also significantly slower in the presence of vitamin E. 
Vitamin E at 0.01% (w/v) was more effective than at 0.04% (w/v). It was reported 
previously that a higher concentration of vitamin E may not necessarily have a higher 
anti-oxidative activity [327]. The effect of temperature on the chemical stability of DHA-
dFdC is shown in Figure 3.2B and 3.2C and Table 3.1. The activation energy of the 
chemical reaction was calculated to be 12.86 kcal/mol. 
 
3.3.4 XRD, UV/Vis and DSC 
 X-ray diffraction pattern showed that the major crystallinity peaks related to dFdC 
at the 2ʘ values of 9.5, 15.4, 19.0, 21.0, 23.0, 27.5, 30.5, and 35.5 were retained in the 
physical mixture of dFdC and DHA, but disappeared in DHA-dFdC (Figure 3.3A). 
UV/Vis scanning revealed that the maximum absorption peak (λmax) of DHA-dFdC in 
methanol was 248 nm, and there is another absorption peak at 300 nm (Figure 3.3B). The 
λmax values of dFdC and DHA were 276 nm and 234 nm, respectively (Figure 3.3B). 
DSC analysis of DHA-dFdC showed a melting point of around 96º C (Figure 3.3C).  
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Table 3.1: First order degradation rate constant of DHA-dFdC in an aqueous formulation 
at room temperature (~22o C), 37º C, and 60º C. Data shown are mean ± S.D. (n = 3). 
 
Temperature k (h-1) 
Room temperature 0.018 ± 0.001 
37° C 0.042 ± 0.005 
60° C 0.106 ± 0.009 
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Figure 3.2. Chemical stability of DHA-dFdC in a Tween 80/ethanol/water 
formulation. (A) The concentration-time curves of DHA-dFdC at room temperature 
(~22oC) in a solution that contained 0, 0.01 or 0.04 % (v/v) of vitamin E. As a control, 
the stability at 4°C was also shown. (B) The effect of temperature on the chemical 
stability of DHA-dFdC in a Tween 80/ethanol/water formulation. (C) Arrhenius plot 
showing the effect of temperature on the rate constant of the degradation of DHA-dFdC 
in a Tween 80/ethanol/water formulation. Data shown are mean from at least 3 repeats, 
and standard deviations were not shown for clarity. 
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Figure 3.3. Physicochemical characterization of DHA-dFdC. (A) XRD patterns of 
DHA-dFdC, dFdC, DHA, and the mixture of dFdC and DHA (1:1, m/m, DHA+dFdC). 
(B) UV/Vis spectra of DHA-dFdC and DHA at various concentrations, and a comparison 
of the UV/Vis spectra of DHA-dFdC, dFdC, DHA, and DHA+dFdC. (C) DSC analyses 
of DHA-dFdC precipitated from ethanol solution (solid line) or ether (dashed line). 
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3.3.5 The cytotoxicity of DHA-dFdC against tumor cells in culture  
The cytotoxicity of DHA-dFdC was evaluated with the NCI-60 DTP Human 
Tumor Cell Lines, and the results are shown in Table 3.2. In addition, the ratios between 
the GI50 values of DHA-dFdC (µM) and those of dFdC against all tested cell lines were 
plotted for comparison (Figure 3.4). Values higher than 1 indicate higher DHA-dFdC 
antiproliferative activity compared to dFdC, in a particular cell line, and the opposite is 
correct for values less than 1 (Figure 3.4). The cytotoxicity of DHA-dFdC was also 
evaluated in various mouse and human pancreatic cancer cell lines (i.e., Panc-02, Bx-
PC3, Panc-1) using an MTT assay, because the NCI-60 human tumor cell lines do not 
include pancreatic tumor cells. In pancreatic cancer cell lines tested, the anti-proliferative 
activity of gem-DHA was found to be concentration dependant (Figure 3.5A-E), which 
was also noticeable with its apoptotic activity against murine pancreatic cancer panc-02 
cells (Figure 3.5F and G). Furthermore, DHA-dFdC exhibited a stronger anti-
proliferative activity compared to dFdC or the physical mixture of dFdC and DHA (1:1, 
molar ratio), while the physical mixture of DHA and dFdC was not more cytotoxic than 
dFdC alone (Figure 3.5A, B, D-F). LDH assay also confirmed that DHA-dFdC was more 
cytotoxic than dFdC in Panc-02 tumor cells (Figure 3.54C).  
In order to understand the effect of the omega-3 polyunsaturated fatty acid nature 
of the DHA (i.e., the docosahexaenoyl group) in the DHA-dFdC on its cytotoxicity 
against tumor cells, the cytotoxicity of ARA-dFdC, a conjugate of dFdC and  arachidonic 
acid (ARA), an omega-6 polyunsaturated fatty acid, was also evaluated in BxPC-3 and 
MIA PaCa-2 cells. ARA-dFdC was not significantly more cytotoxic than dFdC (Figure 
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3.5H), indicating that the omega-3 fatty acid nature of the DHA in the DHA -dFdC is 
critical for the cytotoxicity of DHA-dFdC in tumor cells.  
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Table 3.2:  Anti-proliferative and cytotoxic activities of DHA-dFdC against NCI-60 DTP 
Human Tumor Cell Lines. Values shown are all in in µM. GI50 is the concentration of 
DA-dFdC at which tumor cell growth was inhibited by 50%. TGI is the concentration at 
which tumor cell growth was completely inhibited. LC50 is the concentration at which 
50% of the tumor cells were killed.  
 
 Cell line GI50 
(µM) 
TGI 
(µM) 
LC50 
(µM) 
  DHA-
dFdC 
DHA-
dFdC 
DHA-
dFdC 
Leukemia CCRF-CEM 0.0507 17.9 > 100 
 HL-60 (TB) 0.029 14.8 > 100 
 K-562 0.0674 46.9 > 100 
 MOLT-4 0.0692 13.3 93.1 
 RPMI-8226 0.0538 26.9 > 100 
 SR 0.0141 28.8 > 100 
Non-small cell 
lung cancer 
A549/ATCC 0.0326 15.4 43.8 
 EKVX 0.852 20.4 52.9 
 HOP-62 0.0186 4.47 35.2 
 HOP-92 0.771 34.5 > 100 
 NCI-H226 0.0672 2.75 39.2 
 NCI-H23 0.0157 12.7 56.6 
 NCI-H322M 1.18 19 46 
 NCI-H460 0.0153 11.8 43.3 
 NCI-H522 0.028 14.2 54.1 
Colon Cancer COLO 205 0.143 14.1 50.7 
 HCC-2998 10.6 26.7 67.5 
 HCT-116 0.0311 15.3 44.4 
 HCT-15 1.86 25.3 87.5 
 HT29 0.0683 17.6 45.1 
 KM12 1.05 20.2 51.9 
 SW-620 0.0759 23.2 84.4 
CNS Cancer SF-268 0.0542 12.9 42.3 
 SF-295 0.0791 10.9 37.5 
 SF-539 0.0287 0.538 30.6 
 SNB-19 0.0223 12.4 61.9 
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 SNB-75 0.401 25.1 > 100 
 U251 0.0305 15.2 43.9 
Melanoma LOX IMVI 0.0414 1.07 77.9 
 MALME-3M 10.1 22.8 51.6 
 M14 0.0243 0.21 34.8 
 MDA-MB-435 0.311 18.1 43.3 
 SK-MEL-2 13.2 29.8 67.6 
 SK-MEL-28 10.1 23.3 53.8 
 SK-MEL-5 0.29 17.1 42.1 
 UACC-257 0.518 22.9 56.1 
 UACC-62 0.0494 12.5 43 
Ovarian Cancer IGROV1 3.45 22.5 55.3 
 OVCAR-3 11.1 23.5 49.6 
 OVCAR-4 14.5 28.8 57.2 
 OVCAR-5 0.0821 22.5 63.8 
 OVCAR-8 0.0345 11.4 43.2 
 NCI-ADR-RES 0.0338 14.8 46.9 
 SK-OV-3 0.11 14.2 > 100 
Renal Cancer 786-0 < 0.01 14.2 > 100 
 A498 0.0855 16.1 51.9 
 ACHN < 0.01 10.1 39.4 
 CAKI-1 0.0253 11.7 34.3 
 RXF 393 0.14 15.1 45.1 
 SN12C 0.197 4.49 33.8 
 TK-10 11.5 29.4 74.9 
 UO-31 0.0835 12 37.9 
Prostate Cancer PC-3 10.7 27 67.8 
 DU-145 0.0396 12.5 35.3 
Breast Cancer MCF7 < 0.01 13.4 42.3 
 MDA-MB-231/ATCC 6.82 22.2 53.5 
 HS 578T 17 45.5 > 100 
 BT-549 0.0454 16.3 44.2 
 T-47D 0.0996 17.6 71.9 
Table 3.2 (continued) 
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Figure 3.4: Comparison between the IG50-ratio values between DHA-dFdC and 
dFdC. Note that all the values higher than 1 and less than 10 represent superior anti-
proliferative activity in favor of DHA-dFdC, and the opposite for the values higher than 
0.1 and lower than 1. Red bars represent those cell lines in which DHA-dFdC, at its lower 
concentration, inflicted a % proliferation less than 50% of control (log IG50 values of 
less than - 8.0).    
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Figure 3.5. Anti-cancer activity of DHA-dFdC and molar equivalent concentrations 
of other treatments against cancer cell lines. (A) Anti-proliferative activityagainst 
Panc-02 cells after 48 h, and (B) after 4 h. (C) cytotoxic activity (as represented by LDH 
release) of either DHA-dFdC or dFdC in Panc-02 cells after 48 h. Antiproliferative 
activity of DHA-dFdC and molar equivalent concentrations of other treatments against 
(D) BxPC-3 after 72 h, and (E) Panc-1-Luc after 24 h. (F) Pro-apoptotic activity of DHA-
dFdC against Panc-02 cells determined using flow cytometry after Annexin V-PE and 7-
AAD staining. Quarters are divided as follows: top left, cellular debris, bottom left: live 
cells, top right: late apoptotic cells, and bottom right: early apoptotic cells. (G) Pro-
apoptotic activity of different concentrations of DHA-dFdC. (H) Comparison of the IC50 
values of dFdC or ARA-dFdC in MIA PaCa-2 and in BxPC-3 cells (n.s. is non-
significant). In all sub-figures, except (G), data shown are means ± standard derivations 
(n > 3). 
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3.3.6 Uptake of DHA-dFdC by tumor cells in culture  
The percentage of DHA-dFdC that was taken up by Panc-02 cells after 4 h of 
incubation is shown in Figure 3.6. The % uptake of the DHA-dFdC was about 10-fold 
higher than that of dFdC.   
 
3.3.7 Pharmacokinetics and biodistribution of DHA-dFdC 
 The plasma DHA-dFdC levels in mice at different time points after i.v. injection 
are shown in Figure 3.7A. The elimination of DHA-dFdC in plasma appears to follow a 
bi-exponential model. Selected pharmacokinetics parameters are shown in Figure 3.7B. 
An analysis of the concentrations of DHA-dFdC in several major organs in healthy mice, 
60 min after i.v. injection at a dose of 75 mg/kg showed that the highest percent of the 
injected DHA-dFdC dose was found in mouse pancreas (Figure 3.7C). Therefore, the 
pharmacokinetics of DHA-dFdC in mouse pancreas after pre-determined time points, 
after i.v. injection was also determined and reported in Figure 3.8. For comparison, 
pancreatic levels of dFdC were also measure at pre-determined time points (Figure 3.8). 
It is clear that DHA-dFdC remains in the pancreas for longer periods compared to dFdC. 
For example, after 90 min, the % injected dose ofDHA-dFdC per gram of pancreatic 
tissues was more than 10 times than that of dFdC, in addition, DHA-dFdC is retained in 
the pancreas at a considerable amount in the pancreas after 5 h, while dFdC almost 
disappeared after 90 min.      
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Figure 3.6. Cellular uptake % of DHA-dFdC compared to that of dFdC. Panc-02 
were seeded at 250,000 cells/well in a 12 well-plate for overnight followed by treatment 
with DHA-dFdC (10 µM in DMSO) or dFdC (10 µM in cell culture medium). After 4 h, 
media were removed, cells were lysed, and DHA-dFdC and dFdC were extracted using 
ethyl acetate or acetonitrile, respectively. % cellular uptake following treatment with 
either drug was calculated following analysis with HPLC. Protein content was measured 
in each cell lysate and used to normalize the value of % cellular uptake to the protein 
content. Data represent means ± standard deviations, n = 3-4.   
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A B 
Parameter Value 
A (µg/ml) 334.5 
B (µg/ml) 4.56 
α (min. -1) 0.205 
β (min. -1) 0.012 
t1/2α (min.) 3.38 
t1/2β (min.) 57.75 
AUC (µg.min/ml) 1998.3 
K10 (min. -1) 0.17 
K12 (min. -1) 0.033 
K21 (min. -1) 0.015 
Vc (L/kg) 0.221 
Cmax (µg/ml) 339.05 
Cl (ml/min. Kg) 37.62 
Vss (L/kg) 0.7 
MRT (min.) 18.7 
 
C 
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Figure 3.7. Pharmacokinetics and biodistribution of DHA-dFdC. (A) Plasma DHA-
dFdC concentrations at various time points following i.v. injection into C57BL/6 mice. 
(B) Selected pharmacokinetics parameters when data in A were fitted in two-
compartment model using WinNonLin. (C) Biodistribution profile of DHA-dFdC in 
healthy BALB/c mice 60 min after i.v. injection (DHA-dFdC dose is 75 mg/kg). Data in 
A, and C are mean ± S.D. (n = 3).  
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Figure 3.8. Pancreatic levels of DHA-dFdC compared to those of dFdC following i.v. 
injection of BALB/c mice with either agents (75 mg/kg). After predetermined time 
intervals, mice were sacrificed, and their pancreases were collected, and either DHA-
dFdC or dFdC were extracted and their amounts analyzed by HPLC. Values are means ± 
SD, n = 3). 
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3.3.8 Antitumor activity of DHA-dFdC in mouse models 
Because the cytotoxicity of the DHA-dFdC was up to 105-fold higher than dFdC 
in pancreatic tumor cell lines and DHA-dFdC showed unexpected high distribution in 
mouse pancreas, the in vivo antitumor activity of DHA-dFdC was initially tested in Kras-
Ink4A+/- transgenic mice that spontaneously develop pancreatic ductal adenocarcinoma 
(PDAC). Data in Figure 3.9 showed that treatment with DHA-dFdC significantly 
extended the survival of the transgenic mice. In another animal study involving the 
transgenic mice with pancreatic tumors, a noticeable retardation of tumor progression 
was noticed in DHA-dFdC group, when compared to untreated group (Figure 3.10 and 
Table 3.3). In the untreated group, 4 of 6 mice showed complete transformation of the 
pancreas into pancreatic ductal adenocarcinoma (PDAC), while the other 2 showed 
several foci of PDAC and extensive PanIN-2 and PanIN-3 lesions (Figure 3.10 and Table 
3.3). DHA-dFdC-treated group (65 mg/kg, twice a week for 10 weeks) showed only 2 of 
6 mice with complete PDAC transformation, and another one with almost half the 
pancreas with PDAC transformation. One pancreas appeared to be close to normal, with 
minimum PanIN-1 and -2 lesions. The other two pancreases showed variable expressions 
of PanIN-1, -2, and -3, with only very limited PDAC foci (Figure 3.10, Table 3.3).  
The antitumor activity of DHA-dFdC was then evaluated and compared to that of 
the dFdC or the physical mixture of dFdC and DHA in mice with subcutaneously injected 
human Panc-1-Luc tumor cells. As shown in Figure 3.11A, at the dosing regimen used, 
DHA-dFdC significantly inhibited Panc-1-Luc tumor growth, as compared to the vehicle 
control, but the molar equivalent doses of dFdC alone, DHA alone, or the physical 
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mixture of dFdC and DHA did not significantly inhibit the tumor growth. Shown in 
Figure 3.11B are body weights of mice that were treated with DHA-dFdC. In mice with 
orthotopic Panc-1-Luc tumors, DHA-dFdC effectively inhibited the tumor growth, but 
dFdC at the dosing regimen used did not show significant activity (Figure 3.12A-C). 
Shown in Figure 3.12D is the body weights of mice that were treated with DHA-dFdC. 
H&E staining of the tumor tissues revealed that tumors in mice that were left untreated 
have dense cellular matrix with tightly-packed tumor cells and small intracellular spaces 
(Figure 3.13A). In addition, several areas of necrosis can also be seen in the centers of the 
tumors (lined in green). A similar pattern was observed in tumors in mice that were 
treated with dFdC, but with less necrosis. On the contrary, tumors in mice that were 
treated with DHA-dFdC showed less densely packed cancer cells, with a much larger 
cytoplasm to nucleus ratio and intracellular spaces. Several pyknotic cells with condensed 
chromatin can also be seen in tumors in mice that were treated with DHA-dFdC. Ki-67 
staining showed that there is a significantly lower percent of Ki-67-positive cells in 
tumors in mice that were treated with DHA-dFdC than in mice that were treated with 
dFdC (Figure 3.13A and B). Anti-cleaved lamin A staining showed a significantly higher 
percent of positive staining in tumors in mice that were treated with DHA-dFdC than in 
mice that were untreated (Figure 3.13A and C), whereas the extent of cleaved lamin A 
positive staining in tumors in mice that were treated with dFdC was not different from 
that in mice that were not treated (Figure 3.13A and C). Finally, anti-CD-31 staining 
showed the micro-vessel density (MVD) in tumors in mice that were treated with DHA-
dFdC was significantly lower than in mice that were not treated, but the MVD value in 
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tumors in mice that were treated with dFdC was not different from that in mice that were 
not treated (Figure 3.13A and D).  
      Finally, data in Figure 3.14A showed that DHA-dFdC was much more cytotoxic 
than dFdC, DHA, or a molar equivalent of a mixture of the two against TC-1 cells in 
culture (Figure 3.14 A). DHA-dFdC was more effective than the molar equivalent dose of 
dFdC in controlling the growth of subcutaneously implanted TC-1 mouse lung cancer 
tumors (Figure 3.14B), demonstrating that the in vivo antitumor activity of DHA-dFdC is 
not limited to pancreatic tumors. Shown in Figure 3.14C are the body weights of TC-1 
tumor-bearing mice after they were treated with DHA-dFdC.   
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Figure 3.9: Survival curves of female Kras Ink4A+/- mice treated with DHA-dFdC or 
left treated. Mice were moved to high fat diet at 16-17 weeks of age, DHA-dFdC 
treatment (50 mg/kg, in Tween 80/ethanol/5% mannitol aqueous solution, i.p. injection 
for twice a week) was started when mice were 20 weeks old.   
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Figure 3.10: Histological comparison between spontaneous pancreatic tumors 
extracted from transgenic mice that have been treated with DHA-dFdC or left 
untreated (n=6). 
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Table 3.3: Evaluation of spontaneous pancreatic tumors extracted from transgenic 
mice. 
 
 
# Normal pancreatic tissue PanIN 1 PanIN 2 PanIN 3 Adenocarcinoma 
Control 1 10 % ++ ++++ ++++ 90 % 
Control 2 None ++ ++++ ++++ 100 % 
Control 3 30 % ++ +++ +++ About 70 % 
Control 4 None + +++ +++ 100 % 
Control 5 About 60 % +++ ++ ++ Many foci 
Control 6 More than 80 % +++ + + small focus 
DHA-dFdC 1 About 10 % + +++ +++ > 90 % (poorly 
differentiated) 
DHA-dFdC 2 About 20 % ++ +++ +++ About 80 % 
DHA-dFdC 3 About 35 % +++ +++ ++ Significant area 
(> 65 %), poorly 
differentiated 
DHA-dFdC 4 About 80 % +++ ++ + Small foci 
DHA-dFdC 5 More than 90 % + + + None 
DHA-dFdC 6 More than 90 % + + + None 
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Figure 3.11. Antitumor activity of DHA-dFdC against Panc-1-Luc human 
pancreatic tumors implanted subcutaneously in athymic nude male mice. Tumors 
were implanted (5 x 106 cells/mouse) in the right flank of male athymic nude mice. On 
day 5 following implantation, mice were then treated with DHA-dFdC (50 mg/kg) or 
molar equivalent doses of DHA, dFdC, or DHA + dFdC. Mice in the Vehicle control 
group were injected with a solution of Tween 80/ethanol in 5% of mannitol, which was 
also used to with DHA-dFdC, DHA, and DHA + dFdC mixture, while dFdC alone was 
dissolved in aqueous 50% mannitol solution. All treatments were given by i.p. injection 
as twice/week (A) Tumor growth curves. (B) Mouse body weights during treatments. 
Data are means ± standard errors (n = 5-6), a p < 0.05, DHA-dFdC vs. other groups, n.s. 
is non-significant.   
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3.4 Discussion 
In the present study, we reported the synthesis of DHA-dFdC and presented 1H 
NMR, MS, and LC/MS data to confirm its structure and purity (Scheme 3.1, Figure 3.1). 
DHA-dFdC showed potent broad spectrum antitumor activity as it inhibited the growth of 
all of the NCI-60 human tumor cell lines and several human and mouse pancreatic tumor 
cell lines (Table 3.2, Figure 3.5). Unexpectedly, biodistribution studies showed that 
DHA-dFdC had a relatively high accumulation and slow pancreatic clearance after 
injection into mice. Importantly, DHA-dFdC showed strong antitumor activity in mouse 
models with spontaneously developed pancreatic tumors and also in mice with 
subcutaneous or orthotopic Panc-1 human pancreatic tumor xenografts (Figures 3.9-
3.13).   
            There have been numerous previously reported dFdC derivatives 
[306;308;311;313;315;328-334], including our own [193], but in many cases, the 
derivatives were not as cytotoxic as dFdC alone against tumor cells in culture 
[308;329;330]. Similarly, the chemical conjugates of DHA and other cancer 
chemotherapeutic agents such as paclitaxel, doxorubicin, and 10-hydroxycamptothecin 
were previously reported as well, but the conjugates were not more cytotoxic than the 
original agents in cell culture [290-292]. In fact, these conjugates were considered as 
prodrugs that need to be converted to active forms in order to be effective ([290;292]. 
Therefore, it was unexpected that DHA-dFdC showed a potent broad spectrum antitumor 
activity and was significantly more cytotoxic than dFdC in pancreatic cancer cells (e.g., 
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in BxPC-3 cells, the IC50 value of DHA-dFdC was more than 100,000 fold smaller than 
that of the dFdC).  
DHA-dFdC induced tumor cells (Panc-02) to undergo apoptosis (Figure 3.5F), 
and it is expected that the dFdC formed following hydrolysis of DHA-dFdC contributed 
to the apoptosis. However, the mechanism underlying the potent antitumor activity of 
DHA-dFdC appears to be different from that of dFdC alone, and may not even be 
primarily attributed to the dFdC’s activity in inhibiting nucleic acid synthesis [335-337]. 
For example, although the conjugation of DHA to the 4-NH2 group on the dFdC is 
expected to prevent deanimation, but the mere protection of the 4-NH2 is not sufficient to 
increase the anti-cancer activity of dFdC , as the 4-(N)-stearoyl dFdC, a conjugate of 
dFdC with stearate, and ARA-dFdC, a conjugate of dFdC with ARA, an omega-6 PUFA, 
both in the 4-NH2 position, were not more cytotoxic than dFdC against various dFdC-
sensitive cancer cell lines (e.g., BxPC-3 and MIA PaCa-2) [179;219;338] (Figure 3.5 and 
unpublished data). Therefore, it is unlikely that the potent antitumor activity of the DHA-
dFdC was simply due to the protection of the vulnerable amine group on the dFdC. 
Instead, it appears that the omega-3 PUFA nature of the docosahexaenoyl group in the 
DHA-dFdC (i.e., 22:6 (n-3)) is critical for its strong antitumor activity. ARA is a PUFA 
as well, but it is an omega-6 PUFA, and ARA-dFdC was not more cytotoxic than dFdC in 
the cell lines tested. It was reported previously that epoxy derivatives of DHA, formed by 
the action of cytochrome p450 epoxygenases, exhibited anti-proliferative, anti-
angiogenic, and anti-metastatic activity [339]. It is expected that DHA-dFdC may also 
undergo oxidation at the 4-5, 7-8, 10-11, 13-14, 16-17, or 19-20 sites on its 
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docosahexaenoyl moiety to form the epoxy derivatives, and the oxidized metabolites of 
DHA-dFdC may have antitumor activity. The potent in vitro cytotoxicity of the DHA-
dFdC may also be related to the more extensive cellular uptake of the DHA-dFdC by 
tumor cells in culture than the uptake of the dFdC alone (Figure 3.6), but may not be 
entirely attributed to the increased cellular uptake. For example, when Panc-02 cells were 
treated with DHA-dFdC or dFdC at high concentrations (e.g., 10-100 M), cytotoxicity 
was detected after only 4 h of co-incubation with DHA-dFdC, but not with dFdC (Figure 
3.5B). dFdC, which inhibits nucleic acid synthesis and thus cell proliferation, showed 
significant activity only after prolonged incubation (Figure 3.5A). Therefore, it is 
possible that DHA-dFdC, at least at high concentrations, may cause tumor cell death in a 
cell cycle-independent manner, and the cell death may not be due to the fatty acid nature 
of the DHA in the DHA-dFdC, because DHA alone at the same concentrations did not 
show cytotoxicity after 4 h of co-incubation (Figure 3.5B). Clearly, the mechanisms 
underlying the cytotoxicity of the DHA-dFdC and dFdC alone are not identical, but more 
experiments need to be carried out to understand how DHA-dFdC causes cytotoxicity to 
tumor cells.  
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Figure 3.12. Antitumor activity of DHA-dFdC against Panc-1-Luc human 
pancreatic tumors implanted orthotopically in the pancreases of athymic nude male 
mice. Briefly, mice were anesthetized by isoflurane, and their pancreases were exposed 
following surgical incision. Panc-1-Luc cells (1 x 106 cells/mouse) were injected in the 
pancreas; the peritoneal membrane and skin were closed by sutures and clips, 
respectively. 4 weeks after tumor implantation, mice were randomized, and dosed with 
DHA-dFdC (50 mg/kg, in Tween 80/ethanol/aqueous mannitol solution vehicle) or dFdC 
(26.1 mg/kg, in aqueous mannitol solution). Treatments were given by i.p. injection as 
twice a week. (A) IVIS images of tumors in the 5th week and 8th week after the tumor 
implantation. (B) Tumor weights at the end of the study. (C) Photos of tumors at the end 
of the study.  (D) Mouse body weight change during treatments. Data shown in B and D 
are means ± S.D. (n = 5-7). 
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Figure 3.13. Histological and immunohistochemical evaluation of Panc-1-Luc 
orthotopically-implanted tumors. (A) Representative histological images of tumors 
from nude mice that were treated with DHA-dFdC or dFdC, after the tumor tissues were 
stained with H&E, anti-Ki-67, anti-cleaved lamin A, or anti-CD31 antibodies. (B) 
Percentage of Ki-67 positively-stained cells. (C) Percent of cleaved lamin A positively-
stained cells. (D) The micro-vessel density (MVD) values in tumors determined after 
anti-CD-31 staining, * p < 0.05 against control, ** p < 0.05 against dFdC. 
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Figure 3.14:  Antitumor activity of DHA-dFdC against TC-1 cells in culture and in 
vivo in tumor model in C57BL/6 mice. (A) Anti-proliferative activity of DHA-dFdC 
and molar equivalent concentrations of other treatments against TC-1 murine lung cancer 
cells after 24 h. (B) TC-1 tumor growth curves following treatment with DHA-dFdC or 
dFdC. TC-1 tumor cells were subcutaneously implanted (500,000 cells/mouse) in the 
right flank of female mice, and treatment started in the 7th day following tumor 
implantation. Mice received either DHA-dFdC in Tween 80/ethanol/mannitol aqueous 
solution vehicle (50 mg/kg), dFdC in sterile aqueous 5% mannitol solution (26.1 mg/kg), 
or were kept untreated. Treatments were given by i.p. injection as twice/week. (B) Mouse 
body weight during treatments. a p < 0.05, DHA-dFdC vs. other groups. n = 5-6, data are 
means ± SD). 
 
 145 
Another unexpected finding from this present study is the high accumulation of 
DHA-dFdC in pancreas after i.v. injection into mice (Figures 3.7C and 3.8). The 
relatively high distribution of DHA-dFdC in pancreas was observed in both healthy mice 
(BALB/c) and tumor-bearing mice (C57BL/6 mice with TC-1 tumors and with orthotopic 
M-wnt mammary tumors, data not shown). The high accumulation of DHA-dFdC in the 
pancreas is likely related to the slow elimination of the DHA-dFdC from pancreatic 
tissues (Figure 3.8), but the reason behind the slow pancreatic elimination remains 
unknown. Fukui et al. previously reported that when a diet supplemented with fish oil 
was given to nude mice for 2 weeks (orally), exceptionally high levels of eicosapentanoic 
acid (omega-3 fatty acid, EPA) were detected in the pancreas of the mice, compared to 
control mice that received diet supplemented with corn oil [340]. Significantly higher 
pancreatic accumulation of DHA was also reported in the previously mentioned 
experiment, when compared to control mice, but the difference in DHA levels between 
fish oil-fed and corn-oil fed mice was much less pronounced than that reported with EPA 
(about 1.5 times compared to 5 times, respectively) [340]. Li et al. reported the synthesis 
of a DHA and dFdC conjugate, although no data were presented to demonstrate that the 
DHA was conjugated to the 4-NH2 group of dFdC [341]. Nonetheless, the authors 
showed that DHA seemed to help target dFdC to cells whose membrane is rich in 
phosphatidylethanolamine (PE) [341]. The unexpected high accumulation of DHA-dFdC 
in pancreas prompted the evaluation of its antitumor activity against pancreatic tumors in 
mouse models, and data in Figures 3.9-3.2.13) clearly showed that DHA-dFdC, at a 
dosing regimen that did not cause any observed side effects, effectively inhibit pancreatic 
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tumor growth in mice with spontaneously developed PDAC and with subcutaneous or 
orthotopic Panc-1 human pancreatic tumor xenografts. Panc-1 tumor cells are known to 
be resistant to dFdC, which explains why dFdC at the dosing regimen used did not 
significantly inhibit Panc-1 tumor growth (Figures 3.11, and 3.12). The potent 
cytotoxicity of DHA-dFdC against pancreatic tumor cells and their high accumulation in 
pancreas may partially explain its observed potent antitumor activity against orthotopic 
Panc-1 tumors and PDAC that were spontaneously developed in the Kras-ink4A+/- 
transgenic mice. Additionally, data from the NCI-60 human tumor cell line screening 
clearly showed that DHA-dFdC has potent broad spectrum activity against tumor cells. 
Thus, it is not unreasonable to expect it to show potent antitumor activity against other 
tumors such as renal cell carcinoma and leukemia. In fact, DHA-dFdC was significantly 
more effective than the molar equivalent dose of dFdC in inhibiting the growth of 
subcutaneously implanted mouse TC-1 lung cancer cells (Figure 3.14). Finally, the data 
in the present study clearly illustrated that covalently conjugating two pharmacologically 
active compounds together can generate a new compound with unexpected 
pharmacokinetics and efficacy profiles. Figure 3.4 reveals that the spectrum of 
antiproliferative activity of dFdC is completely different than that of dFdC, confirming 
the development of a new chemical entity.   
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3.5 Conclusion 
            In this report, a novel dFdC derivative (DHA-dFdC) was obtained and purified by 
conjugating DHA to the 4-(N) site of dFdC backbone. DHA-dFdC showed superior anti-
proliferative and cytotoxic activity compared to dFdC or to a molar equivalent dose of 
dFdC + DHA in mixture. Improved antitumor activity was also found in nude mice with 
either subcutaneous or orthotopic Panc-1-Luc human pancreatic tumor xenografts, when 
compared to dFdC. Preliminary biodistribution study revealed that the drug favorably 
accumulates in the pancreas as the major organ of distribution following normalization to 
tissue weight. This trend may contribute to the enhanced antitumor activity of DHA-
dFdC against pancreatic cancer. 
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Chapter 4 
General Conclusion 
 
In this dissertation, some of the most commonly encountered problems and 
drawbacks of currently available chemotherapeutic agents were addressed and were 
successfully overcome utilizing pharmaceutical technology approaches. In one example, 
in order to avoid the undesirable untoward effects related to either the excipient or the 
chemotherapeutic itself, a docetaxel- (DCX-) loaded solid lipid nanoparticle formulation 
(DCX-SLNs) was developed and evaluated as an alternative to the current docetaxel 
formulation that contains Tween 80 among other excipients. A long circulating, Tween 
80-free nanoparticle formulation of DCX will not only avoid Tween 80-related side 
effects, but also is expected to accumulate more DCX in the tumor due to the enhanced 
permeation and retention (EPR) effect.  
Instead of Tween 80, with which hypersensitivity reactions that can be severe are 
associated, mixtures of triglycerides and phospholipids were used to formulate DCX-
SLNs. Various triglycerides with different carbon chain lengths were evaluated as the 
core material for the SLNs, while polyethylene glycol-modified (PEGylated) 
phospholipids were used to stabilize the nanoparticle formulations and to render their 
surfaces hydrophilic to achieve long circulation time. Trimyristin-based formulation was 
found to be more stable and able to release docetaxel at a relatively slower rate, and was 
chosen for further evaluation. Anti-proliferative activity of the DCX-SLNs was found to 
be higher than the conventional Tween 80-based DCX formulation, with IC50 values of 
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0.01, .0056, and 0.06 µM in MDA-MB-231, M-Wnt, and TC-1 cell lines, respectively, 
compared to 0.017, 0.011,and 0.113 µM with conventional DCX formulation. This higher 
anti-proliferative activity was found to be associated with significantly higher apoptotic 
activity as well. The overall better anti-cancer activity in cell culture obtained with DCX-
SLNs may be related to the slow release of DCX from the formulation, with can prolong 
the exposure time of the cells to DCX. In vivo evaluation of DCX-SLNs in murine lung 
cancer tumor model in mice was carried out and it was found that DCX-SLNs have 
significantly more effective than the conventional DCX formulation to slow down tumor 
progress. This effect can be explained by the improved retention of DCX in tumors when 
DCX-SLNs were injected compared to the conventional DCX formulation. DCX-SLNs 
seemed to have a more favorable safety profile as relatively less drug was found in vital 
organs following injection of DCX-SLNs compared to conventional DCX formulation. In 
general, it can be concluded that a new PEGylated nanoparticle-based DCX formulation 
appears to be a better alternative to the currently available DCX formulation due to 
improved antitumor activity and apparent favorable safety profile.   
On the other hand, gemcitabine HCl (dFdC) is one of the standard treatments for 
advanced pancreatic cancer, which is a fatal disease in most cases. Several drawbacks are 
associated with dFdC, including extensive metabolism, mainly via deamination, to yield 
inactive metabolites, in addition to the emergence of various resistance mechanisms 
within the cancer cells.  
 In this dissertation, the omega-3 unsaturated fatty acid docosahexaenoic acid 
(DHA) was covalently conjugated to the 4-N site of dFdC in order to achieve improved 
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effect via the protection of the vulnerable amine group of dFdC against extensive 
deamination and also to take advantage of the reported antitumor activity of DHA. The 
new conjugate (DHA-dFdC) was successfully synthesized and its structure was 
confirmed by means of NMR, mass spectrometry, and LC/MS. X-ray diffraction pattern 
revealed that major crystallization peaks of dFdC completely disappeared, while the 
melting point of the conjugate was found to be around 96º C as indicated by differential 
scanning calorimetry (DSC). Cellular uptake of DHA-dFdC was several folds higher than 
that of dFdC. Surprisingly, it was also found that the conjugate accumulates in the 
pancreas of mice following i.v. injection at higher levels compared with dFdC. When the 
conjugate was evaluated against dFdC-resistant human pancreatic tumors (Panc-1) 
implanted subcutaneously in nude mice, stronger antitumor activity was achieved, 
compared to dFdC alone, DHA alone, or a molar equivalent mixture of the two. Similar 
results were obtained when DHA-dFdC was injected (50 mg/kg, twice a week) in nude 
mice with orthotopic human pancreatic tumors compared to dFdC. Overall, chemical 
conjugation of a natural unsaturated fatty acid with a potential anticancer activity to the 
terminal amine group of dFdC yielded a conjugate with significantly improved antitumor 
activity compared to dFdC, in in vitro and in vivo models. 
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Appendix A 
The effect of microneedles on the skin permeability and antitumor activity of topical 
5-fluorouracil 3 
 
A.1 Introduction 
            Fluorouracil (5-FU) is an anti-metabolite that is used in the treatment of various 
types of cancers, including breast, head and neck, and colorectal cancer [342;343]. The 
fluorinated pyrimidine analog is available in topical formulations, which were approved 
by the United States Food and Drug Administration (FDA) to treat actinic keratosis (non-
cancerous) and superficial basal cell carcinoma (BCC) [344;345]. Approved topical 
products include 5-FU solutions (e.g., Fluoroplex 1% 5-FU solution, Allergan, Inc., 
Irvine, CA, USA), creams (e.g., Efudex, Valeant Pharmaceuticals, Bridgewater, NJ, 
USA), and a 0.5% microsphere-based cream (Carac, Valeant Pharmaceuticals). Other 
reported clinical applications of topical 5-FU include the treatment of nail psoriasis 
[344;346], cholesteatoma [347], lentigo maligna [348], and some premalignant 
ophthalmic conditions [349]. Topical treatment with 5-FU, when applicable, is usually 
preferred to surgical removal of affected lesions for cosmetic reasons, especially for 
multiple lesions and/or facial lesions [350]. Unfortunately, the skin permeability of 
topically applied 5-FU is poor [351-353], likely due to its hydrophilic nature (LogP = -
0.89) [354].  
 
 
 
3 This chapter is based on “Youssef W. Naguib*, Amit Kumar*, and Zhengrong Cui, Acta Pharmaceutica 
Sinica B, 2014. 4 (1): 94-99” 
* Contributed equally 
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The use of the topical 5-FU in BCC is only limited to superficial BCC, and it is 
not recommended for invasive forms of BCC [345;355]. This is based on a study by 
Mohs et al., who reported  that topical application of 5-FU in invasive BCCs can mislead 
clinicians by showing superficial improvement, while the deeper parts of the cancerous 
lesions continue to grow unnoticed [355].  
Several approaches to improve the skin permeation of topical 5-FU have been 
evaluated with different degrees of success. For example, Paolino et al. described the 
formulation of 5-FU-loaded bola-surfactant-based niosomes to improve the percutaneous 
permeation and antitumor activity of 5-FU [352]. The proposed niosomes exhibited an 8-
fold increase in the percutaneous permeation of 5-FU through human skin, as compared 
to 5-FU in an aqueous solution. The 5-FU niosomes were significantly more cytotoxic 
against SKMEL-28 human melanoma cells in culture than 5-FU solution, which was 
attributed to the improved cellular uptake of 5-FU in the niosomes [352]. Other 
researchers reported the use of penetration enhancers such as Azone, isopropyl myristate, 
and lauryl alcohol [353], or the use of improved pharmaceutical  formulation 
technologies (e.g., microemulsions [351] and nanogels [354]), to increase the 
percutaneous permeation of 5-FU. Physical methods to improve the permeability of 5-FU 
have also been evaluated. For example, Fang et al. studied the effect of a series of 
physical methods, namely iontophoresis, electroporation, and erbium:YAG 
(erbium:yttrium-aluminum-garnet) laser, and their combination, on the permeability of 5-
FU [356]. Both iontophoresis and electroporation significantly enhanced the 
percutaneous permeability of 5-FU, but the controlled removal of the stratum corneum by 
 153 
erbium:YAG laser was most effective [356], confirming that it is the stratum corneum 
that limits the skin permeability of 5-FU. Finally, Meidan et al. found that ultrasound 
unexpectedly lowered the permeability of 5-FU through whole rat skin; an effect that was 
attributed to the back-diffusion of 5-FU to the ultrasonic coupling gel filled in the donor 
compartment [357].  
            Microneedle technology has been successfully applied to improve the skin 
permeability of small molecules, macromolecules, vaccines, and even nanoparticles, by 
creating an array of micro-sized holes in the stratum corneum of skin [354;358;358-364]. 
In the present study, the feasibility of using microneedles to improve the skin 
permeability of 5-FU was tested in vitro using mouse skin mounted on Franz diffusion 
apparatus. In addition, the feasibility of using microneedles to improve the in vivo 
antitumor activity of 5-FU was tested by comparing the ability of an FDA-approved 
topical 5-FU cream in inhibiting the growth of subcutaneously implanted B16-F10 
tumors in mice. The 5-FU cream was applied on the mouse skin area where the tumor 
cells were implanted, with or without pretreatment (of the skin area) with a microneedle 
roller. Topical 5-FU is not approved for melanoma treatment, but 5-FU was reported to 
be effective against melanoma cells in culture and in animal models [360;361]. The B16-
F10 tumor cells are implanted subcutaneously in mice, which allows us to indirectly 
evaluate the in vivo permeation of 5-FU across mouse skin as well. 
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A.2 Materials and methods 
 
A.2.1  Materials 
The Dermaroller® microneedle roller was kindly provided by Cynergy, LLC 
(Carson City, NV, USA). There are 192 needles (500 µm in length, 50 µm in base 
diameter) on the roller. The topical 5-FU cream (5%) was from Taro Pharmaceuticals 
USA, Inc. (Hawthorne, NY, USA). Phosphate buffered saline (PBS, pH 7.4), cell culture 
medium, and antibiotics were from Invitrogen (Life Technologies, Carlsbad, CA, USA). 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and 5-FU were 
from Sigma-Aldrich (St. Louis, MO, USA).  
 
A.2.2  In vitro cytotoxicity assay 
            B16-F10 murine melanoma cells were from American Type Culture Collection 
(Manassas, VA, USA) and maintained in Dulbecco’s modified eagle medium (DMEM) 
with 10% (v/v) fetal bovine serum, 10 U/ml of penicillin, and 100 µg/ml of streptomycin. 
Cells (2000/well) were seeded in 96-well plates and incubated overnight at 37°C, 5% 
CO2. Cells were then incubated in the presence of various concentrations of 5-FU in PBS 
solution (pH 7.4) for 24 h or 48 h. Cell viability was determined using an MTT assay 
following the manufacturer's instructions. The formed formazan crystals were dissolved 
in 100 µl of dimethyl sulfoxide, and the absorbance of the resultant solution was 
measured at 570 nm and 630 nm using a BioTek SynergyTM HT Multi-Mode Microplate 
Reader (Winooski, VT, USA). 
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A.2.3 In vitro permeation of 5-FU in solution through mouse skin 
            In vitro permeation assay using Franz diffusion cells was completed as previously 
described [360]. Full thickness dorsal skin from C57BL/6 mice was used in the 
permeation study. Hair was carefully trimmed using an electric clipper 24 h before the 
collection of the skin. The harvested skins were stored at -20oC and used within one 
month. On the day when the permeability study was performed, the skin was also treated 
with the Veet® hair removal cream for 5 min and washed three times with water. The skin 
was then mounted onto the Franz diffusion cells (PermeGear, Inc., Hellertown, PA, 
USA), with the epidermis side facing upward. The receiver compartment contained 5 ml 
of PBS (pH 7.4, 10 mM) and was maintained at 37oC (Haake SC 100 Water Circulator, 
ThermoScientific, Wellington, NH, USA). The diffusion area of the skin was 0.64 cm2. 
The donor compartment was loaded with 400 µg of 5-FU in 400 µl PBS (pH 7.4, 10 mM) 
and covered with parafilm to prevent evaporation. To test the effect of treatment with 
microneedles on the permeation of 5-FU through the skin, the skin samples were also 
treated with a Dermaroller® microneedle roller as previously described before it was 
mounted onto the Franz diffusion cells [362]. Briefly, the skin sample was placed onto 
the flat surface of a balance, and the microneedle roller was rolled in 4 perpendicular 
lines over the skin surface, 5 times each for a total of 20 times, with an applying pressure 
of 600-800 g, which was constantly measured using the balance. At pre-determined time 
points (1, 2, 3, 6, and 18 h), samples (100 µl) were withdrawn from the receiver 
compartment and immediately replenished with fresh medium. The samples were 
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analyzed using HPLC. Chromatography was carried out with an Agilent Technologies 
1260 Infinity HPLC workstation with an Agilent ZORBAX Eclipse Plus C18 column (5 
µm, 4.6 x 150 mm) using a potassium phosphate buffer (40 mM, pH 7.0) as the mobile 
phase. The flow rate was 0.5 ml/min. The detector wavelength was 260 nm. 
 
A.2.4 Animal study 
            Animal study was carried out following the US National Research Council guide 
for the care and use of laboratory animals. The animal protocol was approved by the 
Institutional Animal Care and Use Committee at The University of Texas at Austin. 
Female C57BL/6 mice (8-10 weeks) were from Charles River Laboratories (Wilmington, 
MA, USA). Hair in the lower dorsal skin of anesthetized mice was trimmed using an 
electric clipper.  B16-F10 murine melanoma cells (100,000 cells per mouse) in 100 µl 
DMEM medium were injected subcutaneously in the hair-trimmed area on day 0. On day 
9, mice were divided into 5 groups (5-6 mice per group) and treated as following: mice in 
the 5-FU cream group were treated with the 5-FU cream (100 mg of cream per mouse) on 
the area where the tumor cells were injected using a spatula, once daily for 8 consecutive 
days; mice in the MN + cream group were treated similarly, except that the application 
area was pretreated with the Dermaroller® microneedle roller (MN); mice in the I.V. 5-
FU group were injected with 5-FU in sterile PBS intravenously via the tail vein (50 
mg/kg body weight) on days 9 and 15. Control groups include tumor-bearing mice that 
were left untreated, or tumor-bearing mice that were treated with the microneedle roller 
in the skin area where the tumor cells were injected, but without further treatment with 5-
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FU (i.e., MN group). To treat the mice with the microneedle roller, mice were placed 
onto the flat surface of a balance, and the microneedle roller was rolled over the skin area 
where the tumor cells were injected, 10 times parallel to the mouse length, with an 
applying pressure of around 400 g, which was measured using the balance. Tumor 
growth was monitored, and tumor size measured using a digital caliper. Tumor volume 
was calculated based on the following equation: tumor volume (mm3) = (length x width x 
width)/2. On the last day of the study (day 17), mice were euthanized, and tumor tissues 
were collected and weighed.  
 
A.2.5  Histology and immunohistochemistry 
          Tumor tissues were fixed with a buffered formalin (10%) solution for 48 h and then 
transferred to 70% ethanol until sections were prepared, following paraffin embedding. 
The sections were stained using hematoxylin-eosin (H&E) or anti-CD31 antibody (an 
angiogenesis marker, Abcam, Cambridge, MA, USA) in the Histology and Tissue 
Processing Facility in the Dell Pediatric Research Institute at the University of Texas at 
Austin. Slides were scanned, and images were taken using the ScanScope XT (Aperio 
Technologies, Vista, CA, USA). 
 
A.2.6 Statistical analyses 
            Statistical analyses were completed by performing analysis of variance followed 
by Fisher’s protected least signiﬁcant difference procedure. A p-value of ≤ 0.05 (two-tail) 
was considered signiﬁcant. 
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A.3 Results and discussion 
            Topical 5-FU products are available on the market to treat keratosis and 
superficial BCC. The poor skin permeation of 5-FU limits its application against various 
other cancerous and non-cancerous conditions. Microneedles have been successfully 
applied to improve the skin permeability of large and small molecules, and even 
nanoparticles, by creating micro-sized holes in the stratum corneum of skin [358-362]. 
The feasibility of using microneedles to improve the skin permeability of 5-FU was 
tested in the present study by pretreating skin with a microneedle roller that has solid 
microneedles (500 m in length, 50 m in base diameter) on it. The effect of 
pretreatment of mouse skin with microneedles on the diffusion of 5-FU in solution 
through full thickness mouse skin was initially evaluated in vitro using a Franz diffusion 
apparatus. As expected, the permeation of 5-FU through intact full thickness mouse skin 
was limited, with a flux of 8.93 ± 4.55 µg/cm2/h (Figure A.1). Previously, Fang et al. 
reported a flux value of 1.5-2 g/cm2/h (at pH 5.0) for the diffusion of 5-FU across full 
thickness nude mouse skin 15. However, the permeability of 5-FU through mouse skin 
that was pretreated with microneedles was significantly higher, with a flux of 39.75 ± 
18.50 µg/cm2/h, which is 4.5-fold larger than the flux of 5-FU through intact mouse skin 
(p < 0.05). Clearly, pretreatment of mouse skin with solid microneedles significantly 
increased the permeability of 5-FU through the skin.  
To test whether pretreatment of mouse skin with microneedles can improve the 
antitumor activity of topical 5-FU by increasing its skin permeability, the ability of a 
topical 5-FU cream to inhibit the growth of mouse B16-F10 melanoma cells implanted 
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subcutaneously in the application area in mice was evaluated; the area where the 5-FU 
cream was applied was pretreated with the microneedle roller every time before the 
application of the 5-FU cream. Although 5-FU is not approved for melanoma, it was 
previously shown to be cytotoxic against human and murine melanoma cells 
[354;363;364]. Our own data also confirmed that 5-FU inhibited the growth of the B16-
F10 mouse melanoma cells in culture (Figure A.2). B16-F10 mouse melanoma cells were 
subcutaneously implanted in the rear dorsal area of female C57BL/6 mice. When the 
tumor sizes reached 20-40 mm3 (9 days following implantation), mice were treated with 
the 5-FU cream (5%) topically on the skin area where the tumor cells were implanted. As 
shown in Figure A.3A, B16-F10 tumors grew aggressively if left untreated. Topical 
treatment with 5-FU cream significantly inhibited the tumor growth (Figure A.3A). 
However, the 5-FU cream was significantly more effective in inhibiting the tumor growth 
when the skin area where the 5-FU cream was applied was pretreated with the 
microneedle roller (Figure A.3A). At the end of the study, mice were euthanized to 
collect tumor tissues (Figure A.3B). The average weight of tumors in mice that were 
topically treated with the 5-FU cream without pretreatment with microneedles was 
significantly lower than in mice that were left untreated, but was significantly larger than 
in mice that were treated with microneedles before the application of the 5-FU cream 
(Figure A.3C). In fact, the growth of tumors in mice that were treated with the topical 5-
FU cream following pretreatment of the skin area with the microneedle roller was 
completely inhibited (Figs. 3A-C). The experiment was repeated with twice daily 
applications of 5-FU cream as well, and similar results were obtained (data not shown). 
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The antitumor activity of the topical 5-FU following pretreatment with microneedles was 
not simply due to the mechanical activity of applying the microneedle roller daily on the 
mouse skin area where the tumor cells were subcutaneously injected, because treatment 
with the microneedle roller alone without the 5-FU cream did not show any significant 
effect on the growth of the B16-F10 tumors (Figs. 3A-C). The weights of the mice were 
also monitored during the treatment period, and it was found that the weights of mice that 
were treated with the 5-FU cream following pretreatment with microneedles, once daily 
for 8 consecutive days, did not significantly change (Figure A.3D), suggesting that the 
practice of applying 5-FU cream on a skin area pretreated with microneedles is 
potentially safe.   
 Finally, the tumor tissues were collected from mice and examined 
microscopically. H&E staining revealed that except in mice that were treated with 
microneedles prior to the application of the 5-FU cream (i.e., the MN + 5-FU cream 
group), tumors in all other groups were large (Figure A.4A), with densely packed cells 
and scattered necrotic areas (Figure A.4B). On the contrary, tumors in mice that were 
treated with 5-FU cream after pretreatment with microneedles were smaller (Figure 
A.4A), and the tumor cells were loosely distributed with large intercellular spaces (Figure 
A.4B). Anti-CD31 staining (angiogenesis marker) also revealed that with the exception 
of tumors in mice in the MN + 5-FU cream group, tumors in mice from all other groups 
had well-developed vasculature (Figure A.4C).  
 Taken together, it is clear that the 5-FU cream was more effective when applied 
on a mouse skin area pretreated with microneedles than without microneedle 
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pretreatment in inhibiting the growth of the B16-F10 tumor cells subcutaneously 
implanted underneath the skin (Figure A.3), likely because pretreatment with 
microneedles enabled more 5-FU to permeate through the skin and reach the tumor cells 
in the subcutaneous space. Data in Figure A.1 clearly demonstrated that pretreatment of 
mouse skin with microneedles significantly increased the permeability of 5-FU through 
the skin. As mentioned earlier, topical 5-FU is approved by the FDA for the treatment of 
superficial BCC. BCC is developed from basal cells in basement membrane layer in the 
skin epidermis [365]. The data generated in the present study with the B16-F10 
melanoma cells established in the subcutaneous space underneath the skin dermis layer 
may not accurately predict the effect of topical 5-FU applied on a skin area pretreated 
with microneedles on the growth of spontaneously developed BCC. However, in both 
cases, the 5-FU applied topically onto the skin needs to ‘travel’ across the stratum 
corneum layer before it can reach the live epidermis layer underneath the stratum 
corneum or the subcutaneous space. Data from previous studies showed that the stratum 
corneum layer is rate-limiting in the percutaneous absorption of 5-FU [356]. In addition, 
microneedles’ ability to increase the skin permeability of molecules is mainly attributed 
to the micro-pores or holes created by them in the stratum corneum [360;361]. Therefore, 
the finding that pretreatment of a skin area with microneedles significantly enhanced the 
antitumor activity of topical 5-FU against the subcutaneously implanted mouse B16-F10 
tumor cells may be exploited to improve the efficacy of topical 5-FU against human BCC 
in clinics, especially considering that microneedle rollers, including the one that was used 
in the present study (500 m in needle length, 50 m in based diameter), are already used 
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by humans for cosmetic purposes and dermatology therapy to stimulate collagen and 
elastin production [361;362;366]. Moreover, since the dermal permeability of 5-FU can 
be significantly increased by pretreatment with microneedles, it may become possible to 
evaluate this treatment strategy for transdermal systemic delivery of 5-FU to treat other 
cancers (e.g., breast, colorectal, pancreatic, and gastric cancers), against which 
intravenous 5-FU is currently approved.  
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Figure: A.1 
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Figure A.1. The amounts of 5-FU in PBS solution diffused through full thickness 
mouse skin treated (●) or not treated (○) with microneedles as a function of time. 
Data shown are means ± S.E.M (n = 3). In all the time points tested, with the exception of 
0 h, the values between the microneedle-treated and -untreated groups are significantly 
different (p < 0.05). 
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Figure: A.2 
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Figure A.2. In vitro cytotoxicity of 5-FU against B16-F10 mouse melanoma cells. 
Cells were incubated with various concentrations of 5-FU for 24 h (●) or 48 h (○), and 
cell viability was determined using an MTT assay. Data shown are means (n = 6). 
Standard deviations are not shown for clarity. 
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Figure A.3. The antitumor activity of 5-FU cream applied on mice skins that were 
pre-treated with microneedles and below which B16-F10 melanoma tumors were 
implanted.  (A) The growth curves of B16-F10 tumors in C57BL/6 mice. (B) Digital 
photograph of tumors collected from mice at the end of the study. (C) The weights of 
tumors at the end of the study. (D) The changes in the body weight of B16-F10 tumor-
bearing mice. C57BL/6 mice were subcutaneously injected with B16-F10 tumor cells on 
day 0. Starting on day 9, mice were randomly grouped (n = 5-6) and topically treated 
with 5-FU cream (5%), 100 mg daily for 8 consecutive days, on the skin area where the 
tumor cells were injected. The application area was pretreated (MN + 5-FU cream) or not 
(5-FU cream) with a microneedle roller before the application of the cream. As controls, 
mice were intravenously injected with 5-FU solution (I.V. 5-FU) on days 9 and 15. Other 
controls included tumor-bearing mice left untreated, or tumor-bearing mice treated with a 
microneedle roller in the skin area where the tumor cells were injected (i.e., MN). The 
asterisks (*) in A indicate that the values of the 5-FU cream group and the MN + 5-FU 
cream group are different on days 13, 15, and 17 (p < 0.05). Data shown in A and C are 
mean ± S.E.M (n = 5-6). Standard deviations are not shown in D for clarity (n = 5-6). 
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Figure A.4. Histological and immunohistochemical evaluation of B16-F10 tumors 
following treatment of the tumor-bearing mice with either 5-FU cream with or 
without microneedle pretreatment, or with other controls. Representative images of 
tumor tissues after H&E staining (A: x2, bar = 1mm, B: x10, bar = 200 µm) or anti-CD31 
staining (C: x10, bar = 200 µm).  
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A.4 Conclusions             
In this study, it was shown that the in vitro skin permeability and in vivo 
antitumor activity of topical 5-FU were significantly enhanced when the skin application 
area was pretreated with microneedles. Microneedle technology may be integrated into 
topical 5-FU therapy to improve the clinical outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 172 
Appendix B 
Contribution of authors 
 
 
Dr. Laura M. Lashinger (The University of Texas at Austin) substantially helped with 
some animal expriments mentioned in chapter 3, particularly Figure 3.12. 
Ms. Audrey Rasmussen and Ms. Hannah Ruisi (The University of Texas at Austin) 
helped with some animal experiments mentioned in chapter 3. Ms. Ruisi and Dr. Tinashe 
Ruwona (The University of Texas at Austin) helped with genotyping of transgenic mice 
mentioned in chapter 3. 
Dr. Xinran Li (The University of Texas at Austin) helped with TEM imaging in chapter 
2. 
Dr. Bertha Leticia Rodriguez (The University of Texas at Austin) contributed in Figures 
3.5C, F, and G.   
Dr. Dharmika P. Lansakara-P (the University of Texas at Austin) established the 
synthesis schemes of DHA-dFdC and ARA-dFdC (scheme 3.1), and also contributed 
with the cell culture experiments involving ARA-dFdC (Figure 3.5H). 
Dr. Lan Peng (The University of Texas Southwestern Medical Center) helped with some 
of the information used in Table 3.3. 
Dr. Amit Kumar (The University of Texas at Austin) helped with Figure A.2 and with 
Figure A.3.
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